<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6102400</article-id><article-id pub-id-type="doi">10.3389/fmicb.2018.01873</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Probiotic <italic>Lactobacillus rhamnosus</italic> for Alleviation of <italic>Helicobacter pylori</italic>-Associated Gastric Pathology in East Africa</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Westerik</surname><given-names>Nieke</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/573255/overview"/></contrib><contrib contrib-type="author"><name><surname>Reid</surname><given-names>Gregor</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/413048/overview"/></contrib><contrib contrib-type="author"><name><surname>Sybesma</surname><given-names>Wilbert</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/304876/overview"/></contrib><contrib contrib-type="author"><name><surname>Kort</surname><given-names>Remco</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/521892/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Molecular Cell Biology, VU University Amsterdam</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff><aff id="aff2"><sup>2</sup><institution>Yoba for Life Foundation</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff><aff id="aff3"><sup>3</sup><institution>Canadian R&#x00026;D Centre for Human Microbiome and Probiotics, Lawson Health Research Institute</institution>, <addr-line>London, ON</addr-line>, <country>Canada</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Microbiology and Immunology, and Surgery, Western University</institution>, <addr-line>London, ON</addr-line>, <country>Canada</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Microbiology and Systems Biology, Netherlands Organization for Applied Scientific Research</institution>, <addr-line>Zeist</addr-line>, <country>Netherlands</country></aff><aff id="aff6"><sup>6</sup><institution>ARTIS-Micropia</institution>, <addr-line>Amsterdam</addr-line>, <country>Netherlands</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Teresa Zotta, Consiglio Nazionale delle Ricerche (CNR), Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Yanmei Zhang, Fudan University, China; Jennifer McMillan Noto, Vanderbilt University Medical Center, United States</p></fn><corresp id="c001">*Correspondence: Remco Kort, <email>r.kort@vu.nl</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Food Microbiology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>1873</elocation-id><history><date date-type="received"><day>30</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>25</day><month>7</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Westerik, Reid, Sybesma and Kort.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Westerik, Reid, Sybesma and Kort</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>The probiotic <italic>Lactobacillus rhamnosus</italic> GG (LGG) can play a role in establishing a harmless relationship with <italic>Helicobacter pylori</italic> and reduce gastric pathology in East African populations. <italic>H. pylori</italic> has the ability to inhabit the surface of the mucous layer of the human stomach and duodenum. In the developing world, an estimated 51% of the population is carrier of <italic>H. pylori</italic>, while in some Western countries these numbers dropped below 20%, which is probably associated with improved sanitation and smaller family sizes. Colonization by <italic>H. pylori</italic> can be followed by inflammation of the gastric mucus layer, and is a risk factor in the development of atrophic gastritis, peptic ulcers and gastric cancer. Notwithstanding the higher prevalence of <italic>H. pylori</italic> carriers in developing countries, no equal overall increase in gastric pathology is found. This has been attributed to a less pro-inflammatory immune response to <italic>H. pylori</italic> in African compared to Caucasian populations. In addition, a relatively low exposure to other risk factors in certain African populations may play a role, including the use of non-steroidal anti-inflammatory drugs, smoking, and diets without certain protective factors. A novel approach to the reduction of <italic>H. pylori</italic> associated gastric pathology is found in the administration of the probiotic bacterium <italic>Lactobacillus rhamnosus</italic> yoba 2012 (LRY), the generic variant of LGG. This gastro-intestinal isolate inhibits <italic>H. pylori</italic> by competition for substrate and binding sites as well as production of antimicrobial compounds such as lactic acid. In addition, it attenuates the host&#x02019;s <italic>H. pylori</italic>-induced apoptosis and inflammation responses and stimulates angiogenesis in the gastric and duodenal epithelium. The probiotic LRY is not able to eradicate <italic>H. pylori</italic> completely, but its co-supplementation in antibiotic eradication therapy has been shown to relieve side effects of this therapy. In Uganda, unlike other African countries, gastric pathology is relatively common, presumably resulting from the lack of dietary protective factors in the traditional diet. Supplementation with LRY through local production of probiotic yogurt, could be a solution to establish a harmless relationship with <italic>H. pylori</italic> and reduce gastric pathology and subsequent eradication therapy treatment.</p></abstract><kwd-group><kwd><italic>Lactobacillus rhamnosus</italic> yoba 2012</kwd><kwd><italic>Lactobacillus rhamnosus</italic> GG</kwd><kwd><italic>Helicobacter pylori</italic></kwd><kwd>gastric pathology</kwd><kwd>ulcer</kwd><kwd>eradication therapy</kwd><kwd>Uganda</kwd><kwd>East Africa</kwd></kwd-group><counts><fig-count count="1"/><table-count count="3"/><equation-count count="0"/><ref-count count="102"/><page-count count="13"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p>During the last decade of our probiotic yogurt programs in the East-African countries Uganda, Tanzania, and Kenya, we took note of the high incidence of self-reported ulcers and accompanying stomach pains, as reported decades ago for in particular Northern Tanzania and South-Western Uganda and some regions in Kenya (<xref rid="B90" ref-type="bibr">Tovey and Tunstall, 1975</xref>; <xref rid="B7" ref-type="bibr">Balint, 1998</xref>). Interestingly, during our fieldwork aimed at the stimulation of local production and consumption of probiotic yogurt to improve health and wealth in local communities, we observed a decrease of complaints among consumers and realized that there might be an effect from the intake of probiotic yogurt containing <italic>Lactobacillus rhamnosus</italic> yoba 2012 (LRY), the generic variant of <italic>Lactobacillus rhamnosus</italic> GG (LGG) (<xref rid="B46" ref-type="bibr">Kort and Sybesma, 2012</xref>; <xref rid="B84" ref-type="bibr">Sybesma et al., 2013</xref>), on the reduction of symptoms associated with ulcers.</p><p>Over the last years a number of reviews have been published on <italic>H. pylori</italic> ulcers (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>; <xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>), the prevalence of <italic>H. pylori</italic> and ulcers in different populations (<xref rid="B42" ref-type="bibr">Kidd et al., 1999b</xref>; <xref rid="B76" ref-type="bibr">Roberts et al., 2016</xref>), the interaction between <italic>H. pylori</italic> and LGG (<xref rid="B29" ref-type="bibr">Hamilton-Miller, 2003</xref>; <xref rid="B25" ref-type="bibr">Gotteland et al., 2006</xref>), and effects of LGG administration on ulcers (<xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>,<xref rid="B50" ref-type="bibr">b</xref>). The present paper is, however, the first review that summarizes the incidence of <italic>H. pylori</italic> in East-Africa and its pathology affected by immune responses, genetic factors and environmental factors, including specific regional diets, emphasizing the importance of this topic for East-Africa. In addition, this article reviews effects of the probiotic bacterium LGG on <italic>H. pylori</italic> colonization as well as on inflammation and associated injury of gastric mucosa, in either presence or absence of other treatments. Finally, this review provides substantiation for our on-going probiotic yogurt programs in East-Africa, as reported in this Research Topic in <italic>Frontiers in Microbiology</italic> in another contribution by <xref rid="B96" ref-type="bibr">Westerik et al. (2018)</xref>, to likely reduce <italic>H. pylori</italic>-associated pathology.</p><p>Previous studies also suggested that LGG prevented <italic>H. pylori</italic> colonization, which often occurs in early childhood (<xref rid="B59" ref-type="bibr">Misiewicz et al., 1995</xref>; <xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>; <xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>). It is therefore expected that administration of probiotic yogurt containing LGG to children in resource-poor countries from early childhood, can reduce the incidence of <italic>H. pylori</italic> colonization in the general population. Besides prevention of <italic>H. pylori</italic>, LGG may present an approach to establish and manage a harmless relationship between the host and <italic>H. pylori</italic> when the latter one is already present, counteracting the need for <italic>H. pylori</italic> eradication therapy. <xref rid="B47" ref-type="bibr">Kort et al. (2015)</xref> and <xref rid="B83" ref-type="bibr">Sybesma et al. (2015)</xref> have shown that yogurt containing LRY could be made accessible for people in resource-poor countries in a sustainable way. This is done through providing freeze-dried yogurt starter cultures containing LRY at cost price, in combination with a training program for the local population on standardized and safe yogurt production with locally available equipment.</p></sec><sec><title>Prevalence of <italic>H. pylori</italic> in East Africa</title><p><italic>Helicobacter pylori</italic> is a Gram-negative spiral bacterium that inhabits the surface of the mucous layer of the human stomach and duodenum (upper intestine), usually in a chronic manner, though <italic>H. pylori</italic> colonization can also be temporarily (<xref rid="B31" ref-type="bibr">Hestvik et al., 2010</xref>). The majority of carriers have acquired this bacterium through contact with other human beings before the age of 10 years old, more so in cramped housing areas with poor sanitation practices. When present, <italic>H. pylori</italic> is the dominant microorganism, as very few other bacteria can survive in the stomach.</p><p><italic>Helicobacter pylori</italic> is found in more than 50% of world&#x02019;s population, spread all around the globe (<xref rid="B44" ref-type="bibr">Kodaman et al., 2014</xref>). In 10&#x02013;20% of the carriers, <italic>H. pylori</italic> is believed to be a factor in the development of gastric pathology (<xref rid="B21" ref-type="bibr">Fernando et al., 2001</xref>; <xref rid="B25" ref-type="bibr">Gotteland et al., 2006</xref>; <xref rid="B38" ref-type="bibr">Kate et al., 2013</xref>). Gastric pathology often starts with gastritis (inflammation of the stomach lining), which can become atrophic (degenerating cells) and via gastric metaplasia (abnormal change in tissue) can lead to peptic ulcers and in rare cases to gastric cancer. Duodenal ulcers are much more common than gastric (stomach) ulcers. Over the course of the 20th century, <italic>H. pylori</italic> colonization has become less common in Westernized populations, and in some countries the incidence has dropped below 20% (<xref rid="B24" ref-type="bibr">Go, 2002</xref>; <xref rid="B76" ref-type="bibr">Roberts et al., 2016</xref>). This is probably associated with improved sanitation, smaller family sizes, and frequent use of antibiotics from childhood (<xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>). In contrast, general estimates on the prevalence of <italic>H. pylori</italic> still indicate that over 51% of people living in developing countries, and even 57% of people living on the African continent, are <italic>H. pylori</italic> positive. When taking into account the age of subjects, 52% of African children less than 10 years of age, and over 64% of the African adults are <italic>H. pylori</italic> positive (<xref rid="B101" ref-type="bibr">Zamani et al., 2018</xref>). Hence, the high incidence of <italic>H. pylori</italic> in East-Africa might be a risk factor in the development of gastric pathology among the local population. A summary of studies on the incidence of <italic>H. pylori</italic> and gastric pathology in East-Africa can be found in <bold>Table <xref rid="T1" ref-type="table">1</xref></bold>. <bold>Table <xref rid="T1" ref-type="table">1</xref></bold> shows great variety in the incidence rate between 25 and 87%. This may be due to community-specific differences, but also different diagnostic methods used to determine the presence of <italic>H. pylori</italic> (<xref rid="B74" ref-type="bibr">Ricci et al., 2007</xref>; <xref rid="B101" ref-type="bibr">Zamani et al., 2018</xref>). Notwithstanding, we can conclude that <italic>H. pylori</italic> is a significant risk factor in the development of gastric pathology in East-Africa.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Summary of studies on the incidence of <italic>H. pylori</italic> and gastric pathology in East Africa.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Year</th><th valign="top" align="left" rowspan="1" colspan="1">Country</th><th valign="top" align="left" rowspan="1" colspan="1">Study population</th><th valign="top" align="left" rowspan="1" colspan="1">Study size</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>H. pylori</italic></th><th valign="top" align="left" rowspan="1" colspan="1">Pathogenesis and/or association with <italic>H. pylori</italic></th><th valign="top" align="center" rowspan="1" colspan="1">Comment</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">1988</td><td valign="top" align="left" rowspan="1" colspan="1">Kenya, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Gastritis patients</td><td valign="top" align="left" rowspan="1" colspan="1">187</td><td valign="top" align="left" rowspan="1" colspan="1">57%</td><td valign="top" align="left" rowspan="1" colspan="1">85% of gastritis patients is <italic>H. pylori</italic> carrier</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02018;Most&#x02019; of those who suffered from peptic ulcers or gastric cancer, were <italic>H. pylori</italic> carrier</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B48" ref-type="bibr">Lachlan et al., 1988</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1981&#x02013;1986</td><td valign="top" align="left" rowspan="1" colspan="1">Rwanda</td><td valign="top" align="left" rowspan="1" colspan="1">Endoscopy patients, male/female: 79/94, mean age 35 years</td><td valign="top" align="left" rowspan="1" colspan="1">173</td><td valign="top" align="left" rowspan="1" colspan="1">75%</td><td valign="top" align="left" rowspan="1" colspan="1">29% ulcers of which 100% <italic>H. pylori</italic> carrier 84% gastritis</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B78" ref-type="bibr">Rouvroy et al., 1987</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1993&#x02013;1995</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Gastroscopy patients</td><td valign="top" align="left" rowspan="1" colspan="1">56</td><td valign="top" align="left" rowspan="1" colspan="1">25%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>All H. pylori</italic> was found in the antrum (lower part of the stomach) with accompanying chronic atrophic gastritis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B94" ref-type="bibr">Wabinga, 1996</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Review of seven African serological studies</td><td valign="top" align="left" rowspan="1" colspan="1">Children aged 0&#x02013;10</td><td valign="top" align="left" rowspan="1" colspan="1">635</td><td valign="top" align="left" rowspan="1" colspan="1">50%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Kidd et al., 1999b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Review of seven African serological studies</td><td valign="top" align="left" rowspan="1" colspan="1">Population aged 10&#x02013;60</td><td valign="top" align="left" rowspan="1" colspan="1">1055</td><td valign="top" align="left" rowspan="1" colspan="1">61%</td><td valign="top" align="left" rowspan="1" colspan="1">Asymptomatic</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Kidd et al., 1999b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1999</td><td valign="top" align="left" rowspan="1" colspan="1">Review of 21 African endoscopic studies</td><td valign="top" align="left" rowspan="1" colspan="1">Dyspepsia patients</td><td valign="top" align="left" rowspan="1" colspan="1">3801</td><td valign="top" align="left" rowspan="1" colspan="1">72%</td><td valign="top" align="left" rowspan="1" colspan="1">92% of gastritis; 92% of duodenal ulcers; and 75% in gastric ulcers patients is <italic>H. pylori</italic> carrier</td><td valign="top" align="left" rowspan="1" colspan="1">Duodenal ulcers were four times more common than gastric ulcers. From the dyspeptic subjects suffering from atrophy intestinal metaplasia, on average 77% was found to be carrier of <italic>H. pylori</italic>.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B42" ref-type="bibr">Kidd et al., 1999b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2001</td><td valign="top" align="left" rowspan="1" colspan="1">Zambia</td><td valign="top" align="left" rowspan="1" colspan="1">General population, male/female: 79/142, &#x0003e;18 years</td><td valign="top" align="left" rowspan="1" colspan="1">221</td><td valign="top" align="left" rowspan="1" colspan="1">81%</td><td valign="top" align="left" rowspan="1" colspan="1">7% gastric lesions 2.6% duodenal ulcers, 0.5% gastric ulcers, and 4% gastritis</td><td valign="top" align="left" rowspan="1" colspan="1">35% of the subjects were HIV+, but none of the symptomatic dyspeptic subjects were HIV+, suggesting a protective effect of the HIV virus against pathology of <italic>H. pylori</italic>.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B21" ref-type="bibr">Fernando et al., 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Cancer patients, male/female: 284/549, age range</td><td valign="top" align="left" rowspan="1" colspan="1">833</td><td valign="top" align="left" rowspan="1" colspan="1">87%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B66" ref-type="bibr">Newton et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2010</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Children in Kampala, male/female: 211/216, mean age 4.8 &#x000b1; 3.6 years, age range 0-12</td><td valign="top" align="left" rowspan="1" colspan="1">427</td><td valign="top" align="left" rowspan="1" colspan="1">44%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">No difference in <italic>H. pylori</italic> colonization between different levels of poverty of the children, as defined by the wealth index. The prevalence rate declined in older children, which might be explained by spontaneous eradication, the use of antibiotics or an increase in antibody production</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B31" ref-type="bibr">Hestvik et al., 2010</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2006</td><td valign="top" align="left" rowspan="1" colspan="1">Kenya</td><td valign="top" align="left" rowspan="1" colspan="1">Children 0&#x02013;3, male/female: 103/92, mean age 17.7 months</td><td valign="top" align="left" rowspan="1" colspan="1">195</td><td valign="top" align="left" rowspan="1" colspan="1">46%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B51" ref-type="bibr">Langat et al., 2006</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Dyspepsia patients, male/female: 71/96, mean age 48 &#x000b1; 18 years</td><td valign="top" align="left" rowspan="1" colspan="1">167</td><td valign="top" align="left" rowspan="1" colspan="1">33%</td><td valign="top" align="left" rowspan="1" colspan="1">56% of gastric ulcers and 59% of duodenal ulcers patients is <italic>H. pylori</italic> carrier</td><td valign="top" align="left" rowspan="1" colspan="1">35 of the 167 subjects suffered from either gastric or duodenal ulcers</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B81" ref-type="bibr">Segamwenge et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2014</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Pregnant women, mean age 24 years, age range 15&#x02013;42 years</td><td valign="top" align="left" rowspan="1" colspan="1">447</td><td valign="top" align="left" rowspan="1" colspan="1">45%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Women from five different centers from different regions spread over the country were enrolled in the study. The prevalence in the different centers ranged from 18% in a center in Northern Uganda to 61% in a low-income densely populated division of the capital city.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B6" ref-type="bibr">Baingana et al., 2014</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2015</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda, rural</td><td valign="top" align="left" rowspan="1" colspan="1">Patients with gastrointestinal complaints, male/female: 58/116</td><td valign="top" align="left" rowspan="1" colspan="1">174</td><td valign="top" align="left" rowspan="1" colspan="1">37%</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">The low <italic>H. pylori</italic> carrier rate is explained by the relatively high average age of the subjects, whereby the authors state that <italic>H. pylori</italic> colonization is expected to decrease with age. This is supported by their finding that the highest incidence of <italic>H. pylori</italic> (74%) is in the lowest age bracket (below 21 years) of their study.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B91" ref-type="bibr">Tsongo et al., 2015</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2017</td><td valign="top" align="left" rowspan="1" colspan="1">Uganda</td><td valign="top" align="left" rowspan="1" colspan="1">Symptomatic peptic ulcer patient, male/female: 63/79, mean age 40 &#x000b1; 18 years, age range 13&#x02013;85 years</td><td valign="top" align="left" rowspan="1" colspan="1">142</td><td valign="top" align="left" rowspan="1" colspan="1">22%</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">The study showed that 29% and 48% of the <italic>H. pylori</italic> samples were resistant against the antibiotics clarithromycin, and fluoroquinolones, respectively</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Angol et al., 2017</xref></td></tr></tbody></table></table-wrap></sec><sec><title>Pathogenesis and Other Consequences of <italic>H. pylori</italic> Colonization</title><p>The high incidence of <italic>H. pylori</italic> among East African populations <italic>per se</italic> does not necessarily cause increased levels of gastric pathology, as <italic>H. pylori</italic> induced gastric pathology is influenced by genetic factors of the <italic>H. pylori</italic> strain as well as by specific immune responses of the host. At the same time, it has been reported that <italic>H. pylori</italic> might exert beneficial functions in African populations (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>; <xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>).</p><p>In the context of pathology, <xref rid="B9" ref-type="bibr">Blaser and Atherton (2004)</xref> distinguish two topographic distributions of <italic>H. pylori</italic> induced gastric inflammation, both having different outcomes. Firstly, inflammation could be in the lower part of the stomach only (antral-gastritis), which via a cascade of cell signaling leads to increased gastric acid output and subsequently increases the risk for duodenal ulcers. Secondly, inflammation of the whole stomach (pan-gastritis) could induce cascades of signaling that lead to reduced acid output and associated increased risk for gastric ulcers. This topographic distribution might be determined by genetic factors of <italic>H. pylori</italic> strains as well as environmental factors.</p><p><italic>Helicobacter pylori</italic> strains exhibit a high level of genetic diversity. Certain genetic characteristics of this bacterium have been associated with increased interactions with the host cells. One of the best documented characteristics is the presence of the pathogenicity island <italic>cagA</italic>, which expresses the effector protein CagA that can be injected into epithelial cells (<xref rid="B15" ref-type="bibr">Crabtree et al., 1991</xref>; <xref rid="B11" ref-type="bibr">Bravo et al., 2002</xref>). Connected to the presence of <italic>cagA</italic> is the presence of an active VacA protein (<xref rid="B41" ref-type="bibr">Kidd et al., 1999a</xref>). All <italic>H. pylori</italic> strains contain the <italic>vacA</italic> gene but with a great variance in nucleotide sequence, and not all expressed VacA proteins have the same functional activities. Active VacA causes alterations in epithelial cells and immune cells due to massive vacuolation (<xref rid="B13" ref-type="bibr">Cover and Blanke, 2005</xref>). Strains that both express CagA and active VacA are more likely to cause gastric inflammations and subsequent pathology including peptic ulcers and gastric cancer (<xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>). Other authors identified the <italic>dupA</italic> gene as a virulence factor in <italic>H. pylori</italic> strains that is associated with duodenal ulcers (<xref rid="B38" ref-type="bibr">Kate et al., 2013</xref>). Immune responses against these virulent factors involve Th1 cells, which paradoxically play a major role in <italic>H. pylori</italic> associated pathogenesis by enhancing inflammation (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>).</p><p>With regards to the virulence factors, people in developed countries are found to be colonized by almost equal proportions of <italic>cagA</italic>+ and <italic>cagA</italic>- strains (50% <italic>cagA</italic>+), whereas people in developing countries are predominantly colonized by <italic>cagA</italic>+ strains (79% <italic>cagA</italic>+) (<xref rid="B70" ref-type="bibr">Parsonnet et al., 1997</xref>). However, it has been suggested that people in developing countries respond to <italic>H. pylori</italic> in a way that is associated with a relatively low risk for pathogenesis (<xref rid="B32" ref-type="bibr">Holcombe, 1992</xref>; <xref rid="B60" ref-type="bibr">Mitchell et al., 2009</xref>). For example, <xref rid="B80" ref-type="bibr">Segal et al. (2001)</xref> found that among people in several African countries, gastric cancer accounts only for 2&#x02013;3% of all cancers, whereas the international average is 9% (<xref rid="B69" ref-type="bibr">Parkin, 2004</xref>). This might be due to modulated immune responses to <italic>H. pylori</italic> as a result of infections with a myriad of gastrointestinal pathogens from early life, which primarily occur in developing countries. <xref rid="B60" ref-type="bibr">Mitchell et al. (2009)</xref> quantified the immune response by measuring the IgG1/IgG2 ratio (a marker of the T helper cell response) in Sowetan (South-African), German and Australian symptomatic <italic>H. pylori</italic>-positive subjects. A less pro-inflammatory, IgGI predominant response (IgG1/IgG2 ratio &#x0003e; 1) was observed in 81% of Sowetans, but only in 4.7% of Australians and 4.4% of Germans.</p><p>The realization that <italic>H. pylori</italic> has colonized in the gut of mankind for thousands of years (<xref rid="B23" ref-type="bibr">Ghose et al., 2002</xref>), creating long-standing dynamic equilibriums, led to the assumption that there must be a mutual beneficial relationship (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>; <xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>). <xref rid="B44" ref-type="bibr">Kodaman et al. (2014)</xref> postulate that <italic>H. pylori</italic> co-evolves with host populations and as a consequence, <italic>H. pylori</italic> is less virulent upon colonization in its &#x02018;natural host&#x02019; compared to its colonization in populations from other ethnic origins. The authors reported a strong correlation between <italic>H. pylori</italic> virulence in people of Amerindian origin and the presence of <italic>H. pylori</italic> of African origin and concluded that members of multicultural societies were at higher risk of <italic>H. pylori</italic> associated pathology (<xref rid="B44" ref-type="bibr">Kodaman et al., 2014</xref>).</p><p>In addition to being harmless in many cases, it has even been proposed that <italic>cagA+ H. pylori</italic> could exert beneficial functions in the body. Over the past decennia, gastroesophageal reflux disease (<xref rid="B93" ref-type="bibr">Vicari et al., 1998</xref>), Barrett&#x02019;s esophagus (<xref rid="B92" ref-type="bibr">Vaezi et al., 2000</xref>), esophageal adenocarcinoma (<xref rid="B100" ref-type="bibr">Ye et al., 2004</xref>) and dysfunctional responses to common allergens leading to subsequent childhood asthma and allergic disorders (<xref rid="B14" ref-type="bibr">Cover and Blaser, 2009</xref>) have become more common in the developed world. Recent research has associated the increase of those diseases with the decrease of <italic>cagA</italic>+ <italic>H. pylori</italic> colonized persons. Mechanisms have been proposed on how the absence of <italic>cagA</italic>+ <italic>H. pylori</italic> induced pan-gastritis could lead to an increase in acid production (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>), which in turn could lead to an increased risk of the above mentioned diseases. Indeed, <xref rid="B80" ref-type="bibr">Segal et al. (2001)</xref> found that incidence of gastro-oesophageal reflux and its complications were low in black populations where the incidence of <italic>cagA</italic>+ <italic>H. pylori</italic> is high. However, there was no uniform agreement on the topic, as for example <xref rid="B61" ref-type="bibr">Moon et al. (2009)</xref> found that there is an increase in reflux disease among <italic>H. pylori</italic> positive children in America. However, considering the differences in topographic distribution of gastritis and subsequent different pathologies (<xref rid="B9" ref-type="bibr">Blaser and Atherton, 2004</xref>), the study by <xref rid="B61" ref-type="bibr">Moon et al. (2009)</xref> did not necessarily contradict those of others.</p><p>Another possible beneficial effect of <italic>H. pylori</italic> is protection against tuberculosis, as a study in West Africa indicated that persons with latent tubercular infections have lower chances of re-activating their infections when they are <italic>H. pylori</italic> positive. This is attributed to the fact that <italic>H. pylori</italic> induces the release of IFN-y, an interferon that activates defenses against different types of infections including tuberculosis (<xref rid="B72" ref-type="bibr">Perry et al., 2010</xref>). Finally, <italic>H. pylori</italic> is proposed to play a positive role in body weight regulation: <italic>H. pylori</italic> positive persons produce reduced levels of ghrelin, a weight-regulating hormone that is produced for 60&#x02013;80% in the stomach. <italic>H. pylori</italic> eradication leads to an increased production of ghrelin and a subsequent increase in body weight (<xref rid="B67" ref-type="bibr">Nwokolo et al., 2003</xref>).</p></sec><sec><title>Correlation Between Diet and Lifestyle, and <italic>H. pylori</italic> Associated Pathology</title><p>There is evidence for a connection between <italic>H. pylori</italic> and dyspeptic symptoms (suffering from indigestion), as it has been shown that the odds ratio of a person with dyspeptic symptoms being a carrier of <italic>H. pylori</italic> is higher than the <italic>H. pylori</italic> incidence in the general population (<xref rid="B42" ref-type="bibr">Kidd et al., 1999b</xref>). Furthermore, <italic>H. pylori</italic> eradication leads to long-term cure in the majority of peptic ulcer patients, whereas the natural relapse rate is 70% (<xref rid="B38" ref-type="bibr">Kate et al., 2013</xref>).</p><p>However, this argument is not a definite proof for a causal relationship between <italic>H. pylori</italic> and dyspepsia. It has been suggested that genetic predisposition and environmental factors such as diet, smoking, age and the use of non-steroidal anti-inflammatory drugs (NSAIDs) can lead to high gastric acid production, which in turn can lead to gastric metaplasia and subsequent development of duodenal ulcers (<xref rid="B89" ref-type="bibr">Tovey, 2009</xref>; <xref rid="B38" ref-type="bibr">Kate et al., 2013</xref>). Similarly, the intake of iron supplements has been associated with gastric pathology through the induction of oxidative stress (<xref rid="B65" ref-type="bibr">Naito et al., 1995</xref>; <xref rid="B22" ref-type="bibr">Fisher and Naughton, 2004</xref>). The positive correlation between <italic>H. pylori</italic> and dyspeptic symptoms is attributed to the fact that treatment of duodenal ulcer with acid-reducing medicine facilitates <italic>H. pylori</italic> colonization in the stomach. Hence, the self-reported high incidence of ulcers in Uganda might be partly a result of lifestyle and dietary habits of the local population.</p><p>The hypothesis that <italic>H. pylori</italic> colonization is a result rather than a cause of ulcers, is supported by a retrospective case review of 208 persons, of which 37 were diagnosed with duodenal ulcers. A total number of 32 of the ulcer patients had been suffering from the ulcer for more than 6 months, and all 32 were found to be <italic>H. pylori</italic> positive. Only five patients suffered from ulcers less than 6 months, but all five were found to be <italic>H. pylori</italic> negative (<xref rid="B10" ref-type="bibr">Boulos et al., 2002</xref>). Upon colonization, <italic>H. pylori</italic> might produce toxic substances that inhibit the natural healing of the ulcers, which explains why <italic>H. pylori</italic> eradication leads to highly increased chances of long-term cure of ulcers (<xref rid="B89" ref-type="bibr">Tovey, 2009</xref>; <xref rid="B38" ref-type="bibr">Kate et al., 2013</xref>).</p><p><xref rid="B89" ref-type="bibr">Tovey (2009)</xref> emphasizes the role of dietary protective factors. Dietary fiber intake was one of the first factors that was suspected to be negatively associated with the incidence of ulcers. In an intervention study among 42 culturally rice-eating subjects with a history of duodenal ulcers, 21 were changed to a predominantly unrefined wheat diet, whereas the remaining 21 continued the rice diet. Over a period of 5 years, 81% of the subjects in the rice-eating group reported ulcers, versus only 14% in the wheat-eating group (<xref rid="B56" ref-type="bibr">Malhotra, 1978</xref>). In a Norwegian study, 73 subjects who recently healed from an ulcer (but by whom <italic>H. pylori</italic> was not necessarily eradicated) were assigned to either a high-fiber diet or a low-fiber diet. After 6 months, ulcers had reoccurred in 80% of the subjects on the low-fiber diet, versus only in 45% of the subjects on high-fiber diet (<xref rid="B79" ref-type="bibr">Rydning et al., 1982</xref>).</p><p>A case&#x02013;control study in the United Kingdom compared 78 subjects with duodenal ulcer with 156 matching control subjects (two matches for every ulcer subject). After controlling for total calorie intake, it was found that sugar intake correlated positively and high vegetable fiber intake negatively with ulcers, whereas cereal fibers did not show a specific correlation. After further controlling for smoking, social class and body weight, only the intake of refined sugar remained a significant factor that correlated with ulcer incidence (<xref rid="B40" ref-type="bibr">Katschinski et al., 1990</xref>).</p><p>From an anecdotal study on the incidence of peptic ulcers in sub-Saharan Africa, a correlation between areas with a high incidence of ulcers and high intake of starchy foods, such as bananas, cassava, sweet potato, white wheat flour, white maize flour, and white rice has been suggested. This was opposed to regions with high intake of millet and home-pounded (unrefined) maize, where the incidence of ulcers was low (<xref rid="B89" ref-type="bibr">Tovey, 2009</xref>). However, <xref rid="B89" ref-type="bibr">Tovey (2009)</xref> suggests that it is not the fiber from the unrefined cereal in itself, but rather the phospholipids, sterol esters, and sterol fractions of the lipid components from the cereal fiber fraction that exercises the protective action.</p><p>Other studies identified the plant-derived polyunsaturated fatty acids lipid fraction, such as linoleic and linolenic acid, to have inhibitory effects on <italic>H. pylori</italic>. <italic>In vitro</italic> studies with these components showed to cause cell death to <italic>H. pylori</italic> by damaging the bacterial outer lipid membrane (<xref rid="B88" ref-type="bibr">Thompson et al., 1994</xref>). Besides, certain fatty acids are precursors for prostaglandins which protect the gastric mucosa against injury through increased mucus secretion. Furthermore, arachidonic acid has been shown to improve gastric blood vessel synthesis, thereby speeding up gastric healing processes (<xref rid="B33" ref-type="bibr">Hollander and Tarnawski, 1990</xref>).</p><p>Also in more dated review studies on the relationship between diet and duodenal ulcers <xref rid="B58" ref-type="bibr">Misciagna et al. (2000)</xref> concluded that there were strong indications for a negative correlation between duodenal ulcers and the intake of fiber, mainly soluble fiber from fruit and vegetables, and perhaps polyunsaturated fatty-acids, vitamin A, and vitamin C. However, the study made note of the overall poor quality from the studies that led to this conclusion.</p><p>Other studies suggest a correlation between intake of salt and gastric pathology, partly modulated through <italic>H. pylori</italic>, most commonly in the form of gastric cancer (<xref rid="B95" ref-type="bibr">Wang et al., 2009</xref>). Ulceration has also been mentioned as an outcome of high salt intake (<xref rid="B39" ref-type="bibr">Kato et al., 1992</xref>), though another study found no effect of salt intake on gastric inflammation (<xref rid="B52" ref-type="bibr">Lee et al., 2014</xref>). An <italic>in vitro</italic> study suggested that salt induces expression of virulence factors in <italic>H. pylori</italic> (<xref rid="B98" ref-type="bibr">Xu et al., 2011</xref>), which provides a possible explanation for increased gastric pathology upon high salt intake.</p></sec><sec><title>The Probiotic LGG in <italic>H. pylori</italic> Eradication Therapy</title><p>One of the few other bacteria that can abide under the same gastric circumstances as <italic>H. pylori</italic> (<xref rid="B8" ref-type="bibr">Bezkorovainy, 2001</xref>), being resistant to acid and bile (<xref rid="B20" ref-type="bibr">Fernandez et al., 2003</xref>), is LGG and its generic variant LRY. The probiotic bacterium LGG is world&#x02019;s best documented probiotic bacterium, with many unique characteristics and reported health benefits (<xref rid="B82" ref-type="bibr">Segers and Lebeer, 2014</xref>). Especially to provide access to this bacterium for people in developing countries, the LRY has been incorporated in an affordable probiotic starter culture that enables local communities to make their own probiotic fermented food (<xref rid="B47" ref-type="bibr">Kort et al., 2015</xref>; <xref rid="B97" ref-type="bibr">Westerik et al., 2016</xref>). <italic>H. pylori</italic> can be inhibited in a dose dependent manner by LRY through several pathways, as discussed below, and hence may play a role in the reduction of <italic>H. pylori</italic> related gastric pathology in East Africa (<xref rid="B3" ref-type="bibr">Angol et al., 2017</xref>).</p><p>Currently, the standard method to eradicate <italic>H. pylori</italic> is a three-component therapy treatment that combines acid suppression with two antibiotics for 1 week. This method is also used in East Africa for those who can afford it (<xref rid="B3" ref-type="bibr">Angol et al., 2017</xref>). However, <italic>H. pylori</italic> becomes increasingly resistant against this therapy, and the success rates are dropping below 70% (<xref rid="B55" ref-type="bibr">Malfertheiner et al., 2012</xref>). Furthermore, the therapy typically has low patient compliance due to many side effects such as diarrhea, nausea, vomiting, bloating, and abdominal pain (<xref rid="B4" ref-type="bibr">Armuzzi et al., 2001a</xref>). The European <italic>Helicobacter</italic> Study Group recently acknowledged that certain probiotics show promising results as an adjuvant treatment in reducing side effects of the antibiotic therapy (<xref rid="B55" ref-type="bibr">Malfertheiner et al., 2012</xref>).</p><p>A summary of studies on the role of LGG in <italic>H. pylori</italic> eradication therapy can be found in <bold>Table <xref rid="T2" ref-type="table">2</xref></bold>. All studies confirmed a beneficial effect of LGG in reducing side effects of eradication therapy. Five studies with an average sample size of 70, showed no significant effect on the <italic>H. pylori</italic> eradication rate. However, the sixth study with a sample size of 650 showed <italic>H. pylori</italic> eradication rates of 87% and 73% in the LGG-supplemented group and the control group, respectively.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Summary of studies on the role of LGG in <italic>H. pylori</italic> eradication therapy.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Sample size</th><th valign="top" align="left" rowspan="1" colspan="1">Population</th><th valign="top" align="left" rowspan="1" colspan="1">LGG treatment</th><th valign="top" align="left" rowspan="1" colspan="1">Mode of administration</th><th valign="top" align="left" rowspan="1" colspan="1">Symptoms that have reduced incidence during the treatment week (week 1)</th><th valign="top" align="left" rowspan="1" colspan="1">Effect on eradication rate</th><th valign="top" align="left" rowspan="1" colspan="1">Study type</th><th valign="top" align="left" rowspan="1" colspan="1">Comment</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">120</td><td valign="top" align="left" rowspan="1" colspan="1">Italian, male/female: 54/66, mean age 37 &#x000b1; 11 years</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#x000d7; 10<sup>9</sup> cfu twice daily for 14 days</td><td valign="top" align="left" rowspan="1" colspan="1">Freeze-dried powder, mixed with water</td><td valign="top" align="left" rowspan="1" colspan="1">Taste disturbance 7% vs. 27%, bloating 17% vs. 40%, diarrhea 7% vs. 23% for the treatment group and the control group, respectively</td><td valign="top" align="left" rowspan="1" colspan="1">No effect</td><td valign="top" align="left" rowspan="1" colspan="1">Non-placebo controlled</td><td valign="top" align="left" rowspan="1" colspan="1">In the week after the treatment, the differences remained significant. In the second and the third week after the therapy most side effects faded out in both groups, only bloating remained to have a high incidence, with 7% vs. 17% in the third week.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B5" ref-type="bibr">Armuzzi et al., 2001b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="left" rowspan="1" colspan="1">Italian, male/female: 25/35, mean age 40 &#x000b1; 12 years</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#x000d7; 10<sup>9</sup> cfu twice daily for 14 days</td><td valign="top" align="left" rowspan="1" colspan="1">Freeze-dried powder, mixed with water</td><td valign="top" align="left" rowspan="1" colspan="1">Taste disturbance 23% vs. 50%, diarrhea 3% vs. 27%, nausea 10% vs. 37% for the treatment and the placebo group, respectively</td><td valign="top" align="left" rowspan="1" colspan="1">No effect</td><td valign="top" align="left" rowspan="1" colspan="1">Double-blind placebo controlled</td><td valign="top" align="left" rowspan="1" colspan="1">Differences slowly faded out after 2 weeks. Bloating showed confusing results. In the first week the incidence was 37% vs. 57%, but in subsequent weeks no significant differences were observed.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B4" ref-type="bibr">Armuzzi et al., 2001a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">42</td><td valign="top" align="left" rowspan="1" colspan="1">Italian, male/female: 19/23, age range 18&#x02013;61 years</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#x000d7; 10<sup>9</sup> cfu LGG twice daily for 14 days</td><td valign="top" align="left" rowspan="1" colspan="1">Freeze-dried powder</td><td valign="top" align="left" rowspan="1" colspan="1">Taste disturbance 10% vs. 40%, diarrhea 5% vs. 30% for the treatment and the placebo group, respectively</td><td valign="top" align="left" rowspan="1" colspan="1">No effect</td><td valign="top" align="left" rowspan="1" colspan="1">Triple-blind placebo controlled</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B16" ref-type="bibr">Cremonini et al., 2002</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="left" rowspan="1" colspan="1">Finnish, male/female: 18/29, mean age 56 years, age range 24&#x02013;96 years</td><td valign="top" align="left" rowspan="1" colspan="1">6 &#x000d7; 10<sup>8</sup> cfu twice daily for 7 days, once daily for another 3 weeks</td><td valign="top" align="left" rowspan="1" colspan="1">Milk-based fruit drink also containing <italic>L. rhamnosus</italic> LC; <italic>P. freudenreichii</italic> ssp. <italic>shermanii</italic> JS; and <italic>B. breve</italic> Bb99</td><td valign="top" align="left" rowspan="1" colspan="1">Incidence of side effects is the same, severity of side effects decreases</td><td valign="top" align="left" rowspan="1" colspan="1">No effect</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo-controlled, double-blind randomized pilot study</td><td valign="top" align="left" rowspan="1" colspan="1">The study included analyses of fecal samples, from which was concluded that despite the severe antibiotic treatment, LRY concentrations increased in the probiotic groups, though the levels came back to baseline 6 weeks after the intervention.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B64" ref-type="bibr">Myllyluoma et al., 2005</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">83</td><td valign="top" align="left" rowspan="1" colspan="1">Polish children 5&#x02013;17 years</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>9</sup> cfu LGG twice daily for 7 days</td><td valign="top" align="left" rowspan="1" colspan="1">Freeze-dried powder</td><td valign="top" align="left" rowspan="1" colspan="1">Decrease in diarrhea from 6% vs. 20% between in the treatment and control group, respectively</td><td valign="top" align="left" rowspan="1" colspan="1">No effect</td><td valign="top" align="left" rowspan="1" colspan="1">Double-blind placebo-controlled</td><td valign="top" align="left" rowspan="1" colspan="1">Outcomes on diarrhea reduction not statistically significant.</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B85" ref-type="bibr">Szajewska et al., 2009</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">650</td><td valign="top" align="left" rowspan="1" colspan="1">Croatian, male/female: 283/367, mean age 52 &#x000b1; 11 years</td><td valign="top" align="left" rowspan="1" colspan="1">10<sup>8</sup>&#x02013;10<sup>10</sup> LGG twice daily for 14 days</td><td valign="top" align="left" rowspan="1" colspan="1">Capsule also containing <italic>Bifidobacterium</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Epigastric pain, bloating, flatulence, taste disturbance, nausea, heartburn and a strong reduction of diarrhea from 18% in the placebo group to 4% in the treatment group</td><td valign="top" align="left" rowspan="1" colspan="1">Increased to 87% vs. 73% in the placebo</td><td valign="top" align="left" rowspan="1" colspan="1">Prospective, randomized, placebo-controlled, double-blind, multicenter trial</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B30" ref-type="bibr">Hauser et al., 2015</xref></td></tr></tbody></table></table-wrap></sec><sec><title>Ulcer Prevention and Suppression by LGG</title><p>Apart from its role as co-supplement during <italic>H. pylori</italic> eradication therapy, LGG has a direct inhibitory effect on <italic>H. pylori</italic> and has the potential to directly prevent and reverse gastric pathology in East African populations. Accordingly, in a review of 13 clinical trials reporting on the activity of probiotics on <italic>H. pylori</italic>, <xref rid="B29" ref-type="bibr">Hamilton-Miller (2003)</xref> concludes that probiotics can reduce the severity of <italic>H. pylori</italic> induced pathology, but are not able to eradicate <italic>H. pylori</italic> completely. Three distinct pathways in which LGG counteracts <italic>H. pylori</italic>-induced gastric pathology in the stomach and duodenum can be discriminated: (i) competition for binding sites between LGG and <italic>H. pylori</italic>, (ii) attenuation of the host&#x02019;s <italic>H. pylori</italic>-induced apoptosis, inflammation responses and stimulation of angiogenesis, and (iii) production of anti-microbial substances such as lactic acid.</p><sec><title>Competition for Binding Sites</title><p><italic>In vitro</italic> pre-treatment of epithelial glandular cells (coca-2 cell culture) with 10<sup>7</sup> cfu/ml LGG was found to inhibit subsequent adhesion by <italic>H. pylori</italic> with 53%, and at 10<sup>9</sup> cfu/ml LGG inhibited <italic>H. pylori</italic> with 66%. Competition for binding sites on the epithelial cells was cited as a probable cause (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>) (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>), which appeared to be unrelated to adhesion capacity or organic acid production. Note that binding alone is not a marker for anti-<italic>H. pylori</italic> activity (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>; <xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Interactions of <italic>Lactobacillus rhamnosus</italic> GG or LRY (green) with <italic>Helicobacter pylori</italic> (red) and damaged epithelial cells at the gastric mucosal surface. (A) <italic>H. pylori</italic> upregulates TNF-&#x003b1; (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>) and IL-8 (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>; <xref rid="B77" ref-type="bibr">Rokka et al., 2008</xref>), which in turn upregulate gastrin-17 (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>). <italic>H. pylori</italic> produces urease to reduce the pH in its immediate environment as means of survival (<xref rid="B12" ref-type="bibr">Chen et al., 2010</xref>). (B) Interactions under A are causing inflammation and apoptosis. (C) Gastric inflammation and apoptosis lead to ulceration. (D) LRY binds specifically at affected (mucosal) tissue due to change in microbiota and inflammatory markers (immunoglobulins and cytokines) and qualitative and quantitative changes in the mucus (<xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). LRY upregulates COX-2 protein expression in damaged (ulcerated) stomachs (<xref rid="B35" ref-type="bibr">Jackson et al., 2000</xref>), which induces PGE<sub>2</sub> modulated vascular endothelial growth factor (VEGF) expression, causing angiogenesis (<xref rid="B45" ref-type="bibr">Korhonen et al., 2004</xref>; <xref rid="B87" ref-type="bibr">Tamura et al., 2006</xref>; <xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). LRY inhibits <italic>H pylori</italic> induced IL-8 (interleukin-8) release (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>; <xref rid="B77" ref-type="bibr">Rokka et al., 2008</xref>) and TNF-&#x003b1; release (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>; <xref rid="B43" ref-type="bibr">Kim et al., 2006</xref>). Through suppression of TNF-&#x003b1; and IL-8, <italic>H pylori</italic> induced elevated gastrin-17 levels are attenuated (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>). (E) LRY inhibits <italic>H pylori</italic> adhesion (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>), which appears to be related to competition for binding sites (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>; <xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>). LRY activates Akt/protein kinase B, which is an anti-apoptotic signaling pathway (<xref rid="B99" ref-type="bibr">Yan and Polk, 2002</xref>). LRY blocks p38 MAP, which is a pro-apoptosis (cell survival) signaling pathway (<xref rid="B99" ref-type="bibr">Yan and Polk, 2002</xref>). LRY induces upregulation of ornithine decarboxylase (ODC) (enzyme essential in DNA stabilization and thus cell growth) and B-cell lymphoma 2 (Bcl-2) causing attenuation of apoptosis (<xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). LRY shows antagonistic activity against <italic>H. pylori in vitro</italic>, possibly associated with lactic acid production (<xref rid="B17" ref-type="bibr">De Keersmaecker et al., 2006</xref>; <xref rid="B34" ref-type="bibr">H&#x000fc;tt et al., 2006</xref>). Lactic acid increases the cell wand permeability of <italic>H. pylori</italic>. Besides, production of exopolysaccharide (<xref rid="B2" ref-type="bibr">Allonsius et al., 2017</xref>), lectin (<xref rid="B73" ref-type="bibr">Petrova et al., 2016</xref>), and/or peptides with antimicrobial activity (<xref rid="B53" ref-type="bibr">Lu et al., 2009</xref>) by LRY has been shown to inhibit other pathogenic bacteria, however, this effect has not been shown for <italic>H. pylori</italic> specifically. LRY inhibits urease activity of <italic>H. pylori</italic> (<xref rid="B12" ref-type="bibr">Chen et al., 2010</xref>). (F) LRY upregulates COX-1 (cyclooxygenase-1) protein expression (<xref rid="B35" ref-type="bibr">Jackson et al., 2000</xref>; <xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>) in normal stomachs (ulcer prevention), which increases PGE<sub>2</sub>, which in turn protects mucus cells and increases trans mucosal resistance, thereby protecting mucosal cells from apoptosis (<xref rid="B35" ref-type="bibr">Jackson et al., 2000</xref>; <xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>). LRY upregulates the expression of MUC3 and MUC6 mucin gene, causing significant increase in thickness of the basal mucus layer (<xref rid="B54" ref-type="bibr">Mack et al., 2003</xref>; <xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>). (G) LRY causes upregulation of phosphorylation level of epidermal growth factor receptor (EGF receptor), leading to cell proliferation and angiogenesis and suppresses cell apoptosis (<xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). LRY initially improves epithelial (mucosal) barrier function (<xref rid="B26" ref-type="bibr">Gotteland et al., 2001</xref>; <xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>) but increases <italic>H. pylori</italic> induced barrier deterioration after incubation for 24&#x02013;42 h, hence causes delayed cell membrane damage and leakage (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>).</p></caption><graphic xlink:href="fmicb-09-01873-g001"/></fig><p>Secondly, a study on mice found that during a pre-treatment with a combination of the probiotic bacteria <italic>L. acidophilus</italic> R0052 and <italic>L. rhamnosus</italic> R0011 and subsequent administration of <italic>H. pylori</italic>, colonization was reduced from 100% in the control group to 50% in the probiotic pre-treated group (<xref rid="B36" ref-type="bibr">Johnson-Henry et al., 2004</xref>). Note that this effect has not been proven for LGG specifically.</p><p>In a third study, a decrease in <italic>H. pylori</italic> of 27% was measured in a probiotic intervention among 13 Finnish <italic>H. pylori</italic> positive subjects, based on the well accepted <sup>13</sup>C-Urea Breath Test, which values were an indirect indicator of <italic>H. pylori</italic> density in gastric mucosa. The subjects daily consumed a drink with four probiotic strains, including LGG, with each of the strains in a concentration of 2.5 &#x000d7; 10<sup>9</sup> cfu, for the duration of 56 days, for the duration of 56 days (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>).</p><p>Upon the formation of an ulcer, probably regardless of the causative factor of the ulceration, a spectrum of bacteria other than <italic>H. pylori</italic> has been found to colonize the ulcer surface and to subsequently impair ulcer healing (<xref rid="B19" ref-type="bibr">Elliott et al., 1998</xref>). This has been attributed to a local increase of the pH around the ulcer surface, allowing for strongly increased bacterial growth as compared to normal stomach tissue. The same study found that antibiotic treatment, preferably with a mixture of different antibiotics, increased ulcer healing. Secondly, promotion of lactic acid bacteria (non-specified) in the stomach competed with outgrowth of other possibly harmful bacteria, and increased the rate of ulcer healing. Other studies have indicated specifically the suppressing effect of LGG on several pathogens (<xref rid="B75" ref-type="bibr">Rinkinen et al., 2003</xref>; <xref rid="B34" ref-type="bibr">H&#x000fc;tt et al., 2006</xref>) and its site-specific binding to damaged tissue (<xref rid="B68" ref-type="bibr">Ouwehand et al., 2003</xref>).</p></sec><sec><title>Modulation of Immune Responses</title><p>LGG has shown to modulate local immune responses upon colonization with <italic>H. pylori</italic> or ulceration through the pathways as summarized in <bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>.</p><p><italic>In vitro</italic> pre-treatment of epithelial glandular cells (coca-2 cell culture) with 10<sup>7</sup> cfu/ml LGG was shown to counteract acute <italic>H. pylori</italic> cell membrane leakage by initially tightening the barrier function (<xref rid="B26" ref-type="bibr">Gotteland et al., 2001</xref>; <xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>). However, over time <italic>H. pylori</italic> induced barrier deterioration after incubation for 24&#x02013;42 h, causing delayed cell membrane damage and leakage (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>).</p><p><italic>H. pylori</italic> upregulates TNF-&#x003b1; (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>) and IL-8 (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>; <xref rid="B77" ref-type="bibr">Rokka et al., 2008</xref>), which in turn upregulate gastrin-17. IL-8 is a chemokine which induces inflammation (<xref rid="B77" ref-type="bibr">Rokka et al., 2008</xref>) and TNF-&#x003b1; is a cytokine which induces apoptosis (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>). Gastric inflammation and apoptosis lead to ulceration. Gastrin-17 has been associated with gastric cancer (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>). LGG inhibits <italic>H pylori</italic> induced IL-8 (interleukin-8) release (<xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref>; <xref rid="B77" ref-type="bibr">Rokka et al., 2008</xref>) and TNF-&#x003b1; release (<xref rid="B71" ref-type="bibr">Pe&#x000f1;a and Versalovic, 2003</xref>; <xref rid="B43" ref-type="bibr">Kim et al., 2006</xref>), although it must be noted that another <italic>in vitro</italic> study (<xref rid="B102" ref-type="bibr">Zhang et al., 2005</xref>) showed that high doses of LGG (10<sup>10</sup> cfu) can increase IL-8 production in the absence of <italic>H. pylori</italic>. Through suppression of TNF-&#x003b1; and IL-8, <italic>H pylori</italic> induced elevated gastrin-17 levels were attenuated (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>). A decrease in the hormone gastrin-17 levels was measured in subjects who daily consumed a drink with four probiotic strains including LGG. This study concluded that gastrin-17 could be seen as a maker for non-atrophic gastritis, that probiotics can have a moderate positive influence on non-atrophic gastritis (<xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref>).</p><p>Apart from <italic>H. pylori</italic>, alcohol has been associated with gastric mucosal damage, and alcoholism can be another cause of peptic ulcers. Rats pre-treated with LGG for 3 days responded to the administration of ethanol in a dose-dependent manner: 1 h after administering 10 ml/kg bodyweight of 60% v/v ethanol, the 2 &#x000d7; 10<sup>8</sup> cfu/day pre-treated group did not show any difference, while in the 2 &#x000d7; 10<sup>9</sup> cfu/day group showed 45% smaller gastric lesions as compared to the control group (<xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>). The study concluded that LGG significantly increases the mucosal layer and mucosal integrity (trans mucosal resistance) through upregulated expression of MUC3 (<xref rid="B54" ref-type="bibr">Mack et al., 2003</xref>) and MUC6 mucin genes, thereby counteracting the effects that ethanol normally has on the mucus layer (<xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>). Nevertheless, LGG regulates COX-1 (cyclooxygenase-1) protein expression (<xref rid="B35" ref-type="bibr">Jackson et al., 2000</xref>; <xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>) in normal stomachs, which increases PGE<sub>2</sub>, which protects mucus cells and increases trans mucosal resistance, thereby protecting mucosal cells from apoptosis (<xref rid="B35" ref-type="bibr">Jackson et al., 2000</xref>; <xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref>) and reducing chances of ulceration.</p><p>In a subsequent study of <xref rid="B50" ref-type="bibr">Lam et al. (2007b)</xref>, ulcers were induced by luminal application of acetic acid solution, and LGG was administered in the same manner as described for the previous study, but this time after the ulcer-induction. LGG supplementation had no obvious effects in the control group, but for the ulcer-induced group the larger dose at 10<sup>9</sup> cfu/day induced enhanced cell proliferation of 54%, increased blood vessels generation (angiogenesis) by 41% at the ulcer margins and reduced cell death (apoptosis) by 33%, thereby obtaining significantly reduction of gastric ulcer area by 32% after 3 days of LGG administration. These effects were found to be modulated firstly by the upregulation of phosphorylation level of epidermal growth factor receptor (EGF receptor) causing angiogenesis, cell proliferation and attenuation of apoptosis. Secondly, COX-2 protein expression was upregulated, which induces PGE<sub>2</sub> modulated vascular endothelial growth factor (VEGF) expression, causing angiogenesis (<xref rid="B45" ref-type="bibr">Korhonen et al., 2004</xref>; <xref rid="B87" ref-type="bibr">Tamura et al., 2006</xref>; <xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). Thirdly, LGG upregulates ornithine decarboxylase (ODC) (enzyme essential in DNA stabilization and thus cell growth) and B-cell lymphoma 2 (Bcl-2), thereby causing attenuation of apoptosis (<xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>). The healing continued upon administration of LRY for more days. The study concludes that LGG does not affect the normal gastric mucosa, but normalizes gastric mucosa that is altered by events such as ulcers. LGG has shown to bind specifically at affected (mucosal) tissue due to a change in microbiota and inflammatory markers (immunoglobulins and cytokines) and qualitative and quantitative changes in the mucus. The study has not shown whether it is the live LGG, its metabolites, its cell wall components or other results of gene expression that exert the healing properties of the organism (<xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref>).</p><p>Similarly, in an intervention among 16 human subjects, a 5-day pre-treatment with a probiotic dairy product containing among others 2.4 &#x000d7; 10<sup>9</sup> cfu LGG per day, has been proven to stabilize the intestinal barrier function against increased permeability normally induced by NSAIDs by 77%, thereby preventing the alterations from future pathology such as ulcers (<xref rid="B26" ref-type="bibr">Gotteland et al., 2001</xref>). Heat-killed LGG did not show protective effects. Interestingly, a study by <xref rid="B37" ref-type="bibr">Kamil et al. (2007)</xref> on ulceration in the small intestine of rats as induced by NSAIDs, found that although LGG increased cell proliferation and reduced cell apoptosis, it still aggravated the NSAID induced ulcer size, possibly through increased inflammation.</p><p>Other pathways include the activation of Akt/protein kinase B by LGG, which is an anti-apoptotic signaling pathway (<xref rid="B99" ref-type="bibr">Yan and Polk, 2002</xref>). Secondly, LGG blocks p38 MAP, which is a pro-apoptosis (cell survival) signaling pathway (<xref rid="B99" ref-type="bibr">Yan and Polk, 2002</xref>). Lastly, <italic>H. pylori</italic> produces urease to reduce the pH in its immediate environment as means of survival, which is inhibited by LGG (<xref rid="B12" ref-type="bibr">Chen et al., 2010</xref>), thereby reducing its chances for survival.</p></sec><sec><title>The Probiotic LGG Produces Antimicrobial Substances Against <italic>H. pylori</italic></title><p>Antagonistic activity against <italic>H. pylori in vitro</italic> has been associated with lactic acid production (<xref rid="B17" ref-type="bibr">De Keersmaecker et al., 2006</xref>; <xref rid="B34" ref-type="bibr">H&#x000fc;tt et al., 2006</xref>; <xref rid="B82" ref-type="bibr">Segers and Lebeer, 2014</xref>) and to a lesser extent with the production of other short-chain fatty acids (SCFAs) (<xref rid="B25" ref-type="bibr">Gotteland et al., 2006</xref>). Lactic acid increases the cell wall permeability of <italic>H. pylori</italic> (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). Besides, production of exopolysaccharide (<xref rid="B2" ref-type="bibr">Allonsius et al., 2017</xref>), lectin (<xref rid="B73" ref-type="bibr">Petrova et al., 2016</xref>), and/or peptides with antimicrobial activity (<xref rid="B53" ref-type="bibr">Lu et al., 2009</xref>) by LGG has been shown to inhibit other pathogenic bacteria, however, this effect has not been shown for <italic>H. pylori</italic> specifically. A summary of studies on the effect of LGG on <italic>H. pylori</italic> and gastric pathology can be found in <bold>Table <xref rid="T3" ref-type="table">3</xref></bold>.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Summary of studies on the effect of LGG on <italic>H. pylori</italic> and gastric pathology.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Study sample type</th><th valign="top" align="left" rowspan="1" colspan="1">Pre-treatment</th><th valign="top" align="left" rowspan="1" colspan="1">Treatment</th><th valign="top" align="left" rowspan="1" colspan="1">Mode of LGG administration</th><th valign="top" align="left" rowspan="1" colspan="1">Effect</th><th valign="top" align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><italic>In vitro</italic> coca-2 cell culture</td><td valign="top" align="left" rowspan="1" colspan="1">LGG</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>H. pylori</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Cells inoculated with LGG suspended in DMEM medium</td><td valign="top" align="left" rowspan="1" colspan="1">Inhibition of <italic>H. pylori</italic> adhesion by max 66%</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B62" ref-type="bibr">Myllyluoma et al., 2008</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mice</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>L. rhamnosus</italic> R0011 and <italic>Lactobacillus acidophilus</italic> R0052</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>H. pylori</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Powder dissolved in sterile distilled water, orally administered.</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>H. pylori</italic> colonized 50% of the treatment group vs. 100% in the control group</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B36" ref-type="bibr">Johnson-Henry et al., 2004</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">13 human subjects</td><td valign="top" align="left" rowspan="1" colspan="1">Subjects are <italic>H. pylori</italic> positive</td><td valign="top" align="left" rowspan="1" colspan="1">LGG, 2.5 &#x000d7; 10<sup>9</sup> daily for 54 days</td><td valign="top" align="left" rowspan="1" colspan="1">Probiotic drink also containing <italic>L. rhamnosus</italic> LC; <italic>P. freudenreichii</italic> ssp. <italic>shermanii</italic> JS; and <italic>B. breve</italic> Bb99</td><td valign="top" align="left" rowspan="1" colspan="1">Decrease of <italic>H. pylori</italic> colonization by 27% measured by 13C-UBT</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B63" ref-type="bibr">Myllyluoma et al., 2007</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rats</td><td valign="top" align="left" rowspan="1" colspan="1">LGG 1 &#x000d7; 10<sup>8</sup> or 1 &#x000d7; 10<sup>9</sup> cfu twice daily for 3 days</td><td valign="top" align="left" rowspan="1" colspan="1">Ethanol (inducing ulcers)</td><td valign="top" align="left" rowspan="1" colspan="1">Culture suspended in sterilized water</td><td valign="top" align="left" rowspan="1" colspan="1">Treatment group 45% smaller lesions</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B49" ref-type="bibr">Lam et al., 2007a</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rats</td><td valign="top" align="left" rowspan="1" colspan="1">Acetic acid solution (inducing ulcers)</td><td valign="top" align="left" rowspan="1" colspan="1">LGG 1 &#x000d7; 10<sup>8</sup> or 1 &#x000d7; 10<sup>9</sup> cfu twice daily for 3 days</td><td valign="top" align="left" rowspan="1" colspan="1">Culture suspended in sterilized water</td><td valign="top" align="left" rowspan="1" colspan="1">Reduced gastric ulcer area by 32%</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B50" ref-type="bibr">Lam et al., 2007b</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16 human subjects</td><td valign="top" align="left" rowspan="1" colspan="1">LGG 1 &#x000d7; 10<sup>7</sup> trice daily for 5 days</td><td valign="top" align="left" rowspan="1" colspan="1">NSAIDS</td><td valign="top" align="left" rowspan="1" colspan="1">Commercial dairy product also containing <italic>L. helveticus</italic> and <italic>L. acidophilus</italic></td><td valign="top" align="left" rowspan="1" colspan="1">Reduced gastric permeability by 77% as compared to the non-treatment group</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B26" ref-type="bibr">Gotteland et al., 2001</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rats</td><td valign="top" align="left" rowspan="1" colspan="1">Acetic acid solution (inducing ulcers)</td><td valign="top" align="left" rowspan="1" colspan="1">Lactulose to stimulate growth of LAB</td><td valign="top" align="left" rowspan="1" colspan="1">Lactulose dissolved in drinking water</td><td valign="top" align="left" rowspan="1" colspan="1">Significant reduction of pathogen colonization, significant increased ulcer healing</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B19" ref-type="bibr">Elliott et al., 1998</xref></td></tr></tbody></table></table-wrap></sec></sec><sec><title>A Sustainable Nutritional Intervention in East Africa &#x02013; the Case Study of Uganda</title><p>The absence of dietary protective factors in the traditional starch-based diet in Uganda which mainly consists of bananas, roots and refined cereals, might be a major factor causing the high incidence of ulcers in this country. In rural Uganda, when one experiences dull, sharp or burning pain in the upper abdomen that might indicates dyspepsia, subsequent self-medication with simple and cheap acid suppressors (magnesium trisilicate) is the common practice. Many clinics lack any form of diagnostic equipment and will diagnose ulcers based on description of symptoms only, and subsequently mainly prescribe acid suppressors, though other medicine like histamine antagonists (H2 blockers) and proton-pump inhibitors that suppress acid secretion are also common. The frequent advice is to not use NSAIDs, spices, cigarettes, alcohol or carbonated drinks. Some clinics can perform serum-blood test to detect the presence of <italic>H. pylori</italic> antibodies. Only the minority of the population that enjoys a better economic status might visit private clinics that can perform endoscopy, and might opt for the more expensive eradication therapy. In its clinical guidelines, the Uganda ministry of health advises to primarily treat ulcers with acid suppressors and encourages regular, small and frequent meals, as well as the consumption of milk (Ministry of Health, 2010).</p><p><xref rid="B46" ref-type="bibr">Kort and Sybesma (2012)</xref> and <xref rid="B47" ref-type="bibr">Kort et al. (2015)</xref> described an intervention with the generic variant of LGG, in form of an LRY containing yogurt drink, which is locally produced (<xref rid="B97" ref-type="bibr">Westerik et al., 2016</xref>) and subsequently consumed by resource-poor communities in rural Uganda. We propose such an intervention as a preferred option to alleviate the burden of <italic>H. pylori</italic> induced pathology in resource poor communities. <xref rid="B9" ref-type="bibr">Blaser and Atherton (2004)</xref> mentioned that a beneficial function of <italic>H. pylori</italic> colonization is the reduction of childhood diarrhea. However, when <italic>H. pylori</italic> is in part replaced by LRY, this beneficial function of <italic>H. pylori</italic> might not be lost: LRY has the proven ability to reduce certain types diarrhea (<xref rid="B18" ref-type="bibr">De Roos and Katan, 2000</xref>; <xref rid="B86" ref-type="bibr">Szajewska et al., 2007</xref>; <xref rid="B1" ref-type="bibr">Allen et al., 2010</xref>; <xref rid="B27" ref-type="bibr">Guandalini, 2011</xref>; <xref rid="B28" ref-type="bibr">Guarino et al., 2015</xref>), but without the adverse risks that are associated with <italic>H. pylori</italic> colonization. The local production of probiotic fermented foods can be extended to cereal fermentations, most importantly as a variation on the already popular fermented millet drink (obushera) for the case of Uganda (<xref rid="B97" ref-type="bibr">Westerik et al., 2016</xref>). As it has been suggested that cereal fibers provide additional protection against gastric pathology (<xref rid="B56" ref-type="bibr">Malhotra, 1978</xref>; <xref rid="B89" ref-type="bibr">Tovey, 2009</xref>), this high-fiber drink may exhibit dual protective action against ulcer formation.</p></sec><sec><title>Conclusion</title><p>Studies on the incidence of <italic>H pylori</italic> in East Africa showed widely varying outcomes, ranging between 25 and 87% in various population groups, possibly due to different detection methods used, or differences in study population. Pathology upon <italic>H. pylori</italic> colonization is modulated by several factors including the presence of virulence factors in the <italic>H. pylori</italic> strain, the &#x02018;ethnic&#x02019; origin of the strain, and the specific immune responses of the host. Apart from <italic>H. pylori</italic> colonization, gastric pathology including ulceration is also affected by lifestyle factors, including diet. The right dietary factors have been shown to directly inhibit <italic>H. pylori</italic> as well as reduce <italic>H. pylori</italic> induced pathology.</p><p>It is expected that administering probiotic yogurt to children in developing countries from early childhood can reduce the incidence of <italic>H. pylori</italic> colonization in the general population. Besides prevention of <italic>H. pylori</italic>, LGG or its generic variant LRY may present an approach to establish and manage a harmless relationship between the host and <italic>H. pylori</italic> when the latter one is already present, counteracting the need for <italic>H. pylori</italic> eradication therapy. This alternative approach is cheaper and does not carry the risk of extensive antibiotic resistance (<xref rid="B57" ref-type="bibr">Michetti, 2001</xref>), and is feasible to be implemented sustainably through locally produced yogurt containing LRY.</p><p>It should be noted that major changes in diet might play an equally important role in the prevention and relieve of gastric pathology. In Uganda, locally available foods with protective factors include unrefined wheat, unrefined maize, unrefined rice, millet, soy beans, full-cream milk, spinach, and cabbage (<xref rid="B89" ref-type="bibr">Tovey, 2009</xref>). However, consumption of these products would require education of the population and a change in attitude, since even the rural population as a rule brings produced cereals to an electrical mill, in which the bran is separated from the cereal and subsequently the bran fraction is being used solely for animal feeds. An intervention with the mentioned locally produced yogurt could capture the dietary protective benefits of milk as well as the those of LRY.</p></sec><sec><title>Author Contributions</title><p>NW reviewed the cited literature and drafted the manuscript under guidance of RK. WS, GR, and RK critically read and corrected the draft versions of the article.</p></sec><sec><title>Conflict of Interest Statement</title><p>RK and WS are co-founders of the Yoba for Life Foundation (2009), a non-profit organization, accredited by the Dutch Tax Authorities as a Public Benevolent Institution (PBI), which aims to promote local production and consumption of fermented products in Africa. NW is the Country Coordinator of the Yoba for Life Foundation in Uganda. African fermented products made with the Yoba starter culture, are not marketed by the foundation as such, but the Yoba for Life Foundation stimulates local production and ownership, allowing income-generating activities for African small-scale entrepreneurs in the food sector. The Yoba for Life Foundation distributes and sells ready-to-use sachets with dried bacterial starter cultures at cost price, through a network of partners and volunteers to facilitate the local production of dairy and cereal-based products by controlled bacterial fermentation. The Yoba starter culture contains <italic>Lactobacillus rhamnosus</italic> yoba 2012, which is a generic variant of <italic>Lactobacillus rhamnosus</italic> GG. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> Funding for this study was provided by the Yoba for Life Foundation, Amsterdam, Netherlands.</p></fn></fn-group><ack><p>We acknowledge all the small-scale probiotic yogurt producers who may contribute to the alleviation of <italic>Helicobacter pylori</italic>-associated gastric pathology in East Africa.</p></ack><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>S. J.</given-names></name><name><surname>Martinez</surname><given-names>E. G.</given-names></name><name><surname>Gregorio</surname><given-names>G. V.</given-names></name><name><surname>Dans</surname><given-names>L. F.</given-names></name></person-group> (<year>2010</year>). <article-title>Probiotics for treating acute infectious diarrhoea.</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>11</volume>:<issue>11</issue>. <pub-id pub-id-type="doi">10.1002/14651858.CD003048.pub3</pub-id>
<?supplied-pmid 21069673?><pub-id pub-id-type="pmid">21069673</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allonsius</surname><given-names>C. N.</given-names></name><name><surname>van den Broek</surname><given-names>M. F. L.</given-names></name><name><surname>De Boeck</surname><given-names>I.</given-names></name><name><surname>Kiekens</surname><given-names>S.</given-names></name><name><surname>Oerlemans</surname><given-names>E. F. M.</given-names></name><name><surname>Kiekens</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Interplay between <italic>Lactobacillus rhamnosus</italic> GG and Candida and the involvement of exopolysaccharides.</article-title>
<source><italic>Microb. Biotechnol.</italic></source>
<volume>1</volume>
<fpage>1753</fpage>&#x02013;<lpage>1763</lpage>. <pub-id pub-id-type="doi">10.1111/1751-7915.12799</pub-id>
<?supplied-pmid 28772020?><pub-id pub-id-type="pmid">28772020</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angol</surname><given-names>D. C.</given-names></name><name><surname>Ocama</surname><given-names>P.</given-names></name><name><surname>Ayazika Kirabo</surname><given-names>T.</given-names></name><name><surname>Okeng</surname><given-names>A.</given-names></name><name><surname>Najjingo</surname><given-names>I.</given-names></name><name><surname>Bwanga</surname><given-names>F.</given-names></name></person-group> (<year>2017</year>). <article-title><italic>Helicobacter pylori</italic> from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool.</article-title>
<source><italic>BioMed. Res. Int.</italic></source>
<volume>2017</volume>:<issue>9</issue>. <pub-id pub-id-type="doi">10.1155/2017/5430723</pub-id>
<?supplied-pmid 28555193?><pub-id pub-id-type="pmid">28555193</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armuzzi</surname><given-names>A.</given-names></name><name><surname>Cremonini</surname><given-names>F.</given-names></name><name><surname>Bartolozzi</surname><given-names>F.</given-names></name><name><surname>Canducci</surname><given-names>F.</given-names></name><name><surname>Candelli</surname><given-names>M.</given-names></name><name><surname>Ojetti</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2001a</year>). <article-title>The effect of oral administration of <italic>Lactobacillus</italic> GG on antibiotic-associated gastrointestinal side-effects during <italic>Helicobacter pylori</italic> eradication therapy.</article-title>
<source><italic>Aliment Pharmacol Ther.</italic></source>
<volume>5</volume>
<fpage>163</fpage>&#x02013;<lpage>169</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.00923.x</pub-id>
<?supplied-pmid 11148433?><pub-id pub-id-type="pmid">11148433</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armuzzi</surname><given-names>A.</given-names></name><name><surname>Cremonini</surname><given-names>F.</given-names></name><name><surname>Ojetti</surname><given-names>V.</given-names></name><name><surname>Bartolozzi</surname><given-names>F.</given-names></name><name><surname>Canducci</surname><given-names>F.</given-names></name><name><surname>Candelli</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2001b</year>). <article-title>Effect of <italic>Lactobacillus</italic> GG supplementation on antibiotic-associated gastrointestinal side effects during <italic>Helicobacter pylori</italic> eradication therapy: a pilot study.</article-title>
<source><italic>Digestion</italic></source>
<volume>63</volume>
<fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1159/000051865</pub-id>
<?supplied-pmid 11173893?><pub-id pub-id-type="pmid">11173893</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baingana</surname><given-names>R. K.</given-names></name><name><surname>Kiboko Enyaru</surname><given-names>J.</given-names></name><name><surname>Davidsson</surname><given-names>L.</given-names></name></person-group> (<year>2014</year>). <article-title><italic>Helicobacter pylori</italic> infection in pregnant women in four districts of Uganda: role of geographic location, education and water sources.</article-title>
<source><italic>BMC Public Health.</italic></source>
<volume>4</volume>:<issue>915</issue>. <pub-id pub-id-type="doi">10.1186/1471-2458-14-915</pub-id>
<?supplied-pmid 25190150?><pub-id pub-id-type="pmid">25190150</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balint</surname><given-names>G. A.</given-names></name></person-group> (<year>1998</year>). <article-title>Selected gastrointestinal pathologies in tropical sub-Saharan Africa.</article-title>
<source><italic>Bull. World Health Organ.</italic></source>
<volume>76</volume>
<fpage>207</fpage>&#x02013;<lpage>212</lpage>. <?supplied-pmid 9648363?><pub-id pub-id-type="pmid">9648363</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bezkorovainy</surname><given-names>A.</given-names></name></person-group> (<year>2001</year>). <article-title>Probiotics: determinants of survival and growth in the gut.</article-title>
<source><italic>Am. J. Clin. Nutr.</italic></source>
<volume>73</volume>
<fpage>399s</fpage>&#x02013;<lpage>405s</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/73.2.399s</pub-id>
<?supplied-pmid 11157348?><pub-id pub-id-type="pmid">11157348</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaser</surname><given-names>M. J.</given-names></name><name><surname>Atherton</surname><given-names>J. C.</given-names></name></person-group> (<year>2004</year>). <article-title><italic>Helicobacter pylori</italic> persistence: biology and disease.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>1</volume>
<fpage>321</fpage>&#x02013;<lpage>333</lpage>. <pub-id pub-id-type="doi">10.1172/JCI20925</pub-id>
<?supplied-pmid 14755326?><pub-id pub-id-type="pmid">14755326</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulos</surname><given-names>P. B.</given-names></name><name><surname>Botha</surname><given-names>A.</given-names></name><name><surname>Hobsley</surname><given-names>M.</given-names></name><name><surname>Holton</surname><given-names>J.</given-names></name><name><surname>Oshowo</surname><given-names>A. O.</given-names></name><name><surname>Tovey</surname><given-names>F. I.</given-names></name></person-group> (<year>2002</year>). <article-title>Possible absence of <italic>Helicobacter pylori</italic> in the early stages of duodenal ulceration.</article-title>
<source><italic>QJM</italic></source>
<volume>1</volume>
<fpage>749</fpage>&#x02013;<lpage>752</lpage>. <pub-id pub-id-type="doi">10.1093/qjmed/95.11.749</pub-id>
<?supplied-pmid 12391387?><pub-id pub-id-type="pmid">12391387</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bravo</surname><given-names>L. E.</given-names></name><name><surname>van Doorn</surname><given-names>L.-J.</given-names></name><name><surname>Realpe</surname><given-names>J. L.</given-names></name><name><surname>Correa</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>Virulence-associated genotypes of <italic>Helicobacter pylori</italic>: do they explain the African enigma?</article-title>
<source><italic>Am. J. Gastroenterol.</italic></source>
<volume>97</volume>
<fpage>2839</fpage>&#x02013;<lpage>2842</lpage>. <pub-id pub-id-type="doi">10.1111/j.1572-0241.2002.07031.x</pub-id>
<?supplied-pmid 12425557?><pub-id pub-id-type="pmid">12425557</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>H.-P.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>In vitro screening of <italic>Lactobacilli</italic> with antagonistic activity against <italic>Helicobacter pylori</italic> from traditionally fermented foods.</article-title>
<source><italic>J. Dairy Sci.</italic></source>
<volume>93</volume>
<fpage>5627</fpage>&#x02013;<lpage>5634</lpage>. <pub-id pub-id-type="doi">10.3168/jds.2010-3449</pub-id>
<?supplied-pmid 21094733?><pub-id pub-id-type="pmid">21094733</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cover</surname><given-names>T. L.</given-names></name><name><surname>Blanke</surname><given-names>S. R.</given-names></name></person-group> (<year>2005</year>). <article-title><italic>Helicobacter pylori</italic> VacA, a paradigm for toxin multifunctionality.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>3</volume>
<fpage>320</fpage>&#x02013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1095</pub-id>
<?supplied-pmid 15759043?><pub-id pub-id-type="pmid">15759043</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cover</surname><given-names>T. L.</given-names></name><name><surname>Blaser</surname><given-names>M. J.</given-names></name></person-group> (<year>2009</year>). <article-title><italic>Helicobacter pylori</italic> in health and disease.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>136</volume>
<fpage>1863</fpage>&#x02013;<lpage>1873</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.073</pub-id>
<?supplied-pmid 19457415?><pub-id pub-id-type="pmid">19457415</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crabtree</surname><given-names>J. E.</given-names></name><name><surname>Taylor</surname><given-names>J. D.</given-names></name><name><surname>Heatley</surname><given-names>R. V.</given-names></name><name><surname>Shallcross</surname><given-names>T. M.</given-names></name><name><surname>Rathbone</surname><given-names>B. J.</given-names></name><name><surname>Wyatt</surname><given-names>J. I.</given-names></name><etal/></person-group> (<year>1991</year>). <article-title>Mucosal IgA recognition of <italic>Helicobacter pylori</italic> 120 kDa protein, peptic ulceration, and gastric pathology.</article-title>
<source><italic>Lancet</italic></source>
<volume>10</volume>
<fpage>332</fpage>&#x02013;<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1016/0140-6736(91)90477-7</pub-id>
<?supplied-pmid 1677696?><pub-id pub-id-type="pmid">1677696</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cremonini</surname><given-names>F.</given-names></name><name><surname>Di Caro</surname><given-names>S.</given-names></name><name><surname>Covino</surname><given-names>M.</given-names></name><name><surname>Armuzzi</surname><given-names>A.</given-names></name><name><surname>Gabrielli</surname><given-names>M.</given-names></name><name><surname>Santarelli</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Effect of different probiotic preparations on anti-<italic>Helicobacter pylori</italic> therapy-related side effects: a parallel group, triple blind, placebo-controlled study.</article-title>
<source><italic>Am. J. Gastroenterol.</italic></source>
<volume>97</volume>
<fpage>2744</fpage>&#x02013;<lpage>2749</lpage>. <pub-id pub-id-type="doi">10.1111/j.1572-0241.2002.07063.x</pub-id>
<?supplied-pmid 12425542?><pub-id pub-id-type="pmid">12425542</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Keersmaecker</surname><given-names>S. C.</given-names></name><name><surname>Verhoeven</surname><given-names>T. L. A.</given-names></name><name><surname>Desair</surname><given-names>J.</given-names></name><name><surname>Marchal</surname><given-names>K.</given-names></name><name><surname>Vanderleyden</surname><given-names>J.</given-names></name><name><surname>Nagy</surname><given-names>I.</given-names></name></person-group> (<year>2006</year>). <article-title>Strong antimicrobial activity of <italic>Lactobacillus rhamnosus</italic> GG against <italic>Salmonella typhimurium</italic> is due to accumulation of lactic acid.</article-title>
<source><italic>FEMS Microbiol. Lett.</italic></source>
<volume>1</volume>
<fpage>89</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6968.2006.00250.x</pub-id>
<?supplied-pmid 16684107?><pub-id pub-id-type="pmid">16684107</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Roos</surname><given-names>N. M.</given-names></name><name><surname>Katan</surname><given-names>M. B.</given-names></name></person-group> (<year>2000</year>). <article-title>Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998.</article-title>
<source><italic>Am. J. Clin. Nutr.</italic></source>
<volume>71</volume>
<fpage>405</fpage>&#x02013;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1093/ajcn/71.2.405</pub-id>
<?supplied-pmid 10648252?><pub-id pub-id-type="pmid">10648252</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>S. N.</given-names></name><name><surname>Buret</surname><given-names>A.</given-names></name><name><surname>McKnight</surname><given-names>W.</given-names></name><name><surname>Miller</surname><given-names>M. J.</given-names></name><name><surname>Wallace</surname><given-names>J. L.</given-names></name></person-group> (<year>1998</year>). <article-title>Bacteria rapidly colonize and modulate healing of gastric ulcers in rats.</article-title>
<source><italic>Am. J. Physiol. Gastrointest Liver Physiol.</italic></source>
<volume>275</volume>
<fpage>G425</fpage>&#x02013;<lpage>G432</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.1998.275.3.G425</pub-id>
<?supplied-pmid 9724253?><pub-id pub-id-type="pmid">9724253</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez</surname><given-names>M. F.</given-names></name><name><surname>Boris</surname><given-names>S.</given-names></name><name><surname>Barbes</surname><given-names>C.</given-names></name></person-group> (<year>2003</year>). <article-title>Probiotic properties of human <italic>Lactobacilli</italic> strains to be used in the gastrointestinal tract.</article-title>
<source><italic>J. Appl. Microbiol.</italic></source>
<volume>94</volume>
<fpage>449</fpage>&#x02013;<lpage>455</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2672.2003.01850.x</pub-id><pub-id pub-id-type="pmid">12588553</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>N.</given-names></name><name><surname>Holton</surname><given-names>J.</given-names></name><name><surname>Zulu</surname><given-names>I.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name><name><surname>Mwaba</surname><given-names>P.</given-names></name><name><surname>Kelly</surname><given-names>P.</given-names></name></person-group> (<year>2001</year>). <article-title><italic>Helicobacter pylori</italic> Infection in an Urban African population.</article-title>
<source><italic>J. Clin. Microbiol.</italic></source>
<volume>1</volume>
<fpage>1323</fpage>&#x02013;<lpage>1327</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.39.4.1323-1327.2001</pub-id>
<?supplied-pmid 11283050?><pub-id pub-id-type="pmid">11283050</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>A. E.</given-names></name><name><surname>Naughton</surname><given-names>D. P.</given-names></name></person-group> (<year>2004</year>). <article-title>Iron supplements: the quick fix with long-term consequences.</article-title>
<source><italic>Nutr. J.</italic></source>
<volume>16</volume>:<issue>2</issue>. <pub-id pub-id-type="doi">10.1186/1475-2891-3-2</pub-id>
<?supplied-pmid 14728718?><pub-id pub-id-type="pmid">14728718</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghose</surname><given-names>C.</given-names></name><name><surname>Perez-Perez</surname><given-names>G. I.</given-names></name><name><surname>Dominguez-Bello</surname><given-names>M.-G.</given-names></name><name><surname>Pride</surname><given-names>D. T.</given-names></name><name><surname>Bravi</surname><given-names>C. M.</given-names></name><name><surname>Blaser</surname><given-names>M. J.</given-names></name></person-group> (<year>2002</year>). <article-title>East Asian genotypes of <italic>Helicobacter pylori</italic> strains in amerindians provide evidence for its ancient human carriage.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>99</volume>
<fpage>15107</fpage>&#x02013;<lpage>15111</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.242574599</pub-id>
<?supplied-pmid 12417749?><pub-id pub-id-type="pmid">12417749</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>M. F.</given-names></name></person-group> (<year>2002</year>). <article-title>Natural history and epidemiology of <italic>Helicobacter pylori</italic> infection.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>1</volume>
<fpage>3</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.0160s1003.x</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotteland</surname><given-names>M.</given-names></name><name><surname>Brunser</surname><given-names>O.</given-names></name><name><surname>Cruchet</surname><given-names>S.</given-names></name></person-group> (<year>2006</year>). <article-title>Systematic review: are probiotics useful in controlling gastric colonization by <italic>Helicobacter pylori</italic>?</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>1</volume>
<fpage>1077</fpage>&#x02013;<lpage>1086</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2036.2006.02868.x</pub-id>
<?supplied-pmid 16611267?><pub-id pub-id-type="pmid">16611267</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotteland</surname><given-names>M.</given-names></name><name><surname>Cruchet</surname><given-names>S.</given-names></name><name><surname>Verbeke</surname><given-names>S.</given-names></name></person-group> (<year>2001</year>). <article-title>Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>17</volume>
<fpage>11</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.00898.x</pub-id>
<?supplied-pmid 11136273?><pub-id pub-id-type="pmid">11136273</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guandalini</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Probiotics for prevention and treatment of diarrhea.</article-title>
<source><italic>J. Clin. Gastroenterol.</italic></source>
<volume>45</volume>
<fpage>S149</fpage>&#x02013;<lpage>S153</lpage>. <pub-id pub-id-type="doi">10.1097/MCG.0b013e3182257e98</pub-id>
<?supplied-pmid 21992955?><pub-id pub-id-type="pmid">21992955</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guarino</surname><given-names>A.</given-names></name><name><surname>Guandalini</surname><given-names>S.</given-names></name><name><surname>Vecchio</surname><given-names>A. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Probiotics for prevention and treatment of diarrhea.</article-title>
<source><italic>J. Clin. Gastroenterol.</italic></source>
<volume>49</volume>
<fpage>S37</fpage>&#x02013;<lpage>S45</lpage>. <pub-id pub-id-type="doi">10.1097/MCG.0000000000000349</pub-id>
<?supplied-pmid 26447963?><pub-id pub-id-type="pmid">26447963</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton-Miller</surname><given-names>J. M. T.</given-names></name></person-group> (<year>2003</year>). <article-title>The role of probiotics in the treatment and prevention of <italic>Helicobacter pylori</italic> infection.</article-title>
<source><italic>Int. J. Antimicrob. Agents.</italic></source>
<volume>22</volume>
<fpage>360</fpage>&#x02013;<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1016/S0924-8579(03)00153-5</pub-id>
<?supplied-pmid 14522098?><pub-id pub-id-type="pmid">14522098</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>G.</given-names></name><name><surname>Salkic</surname><given-names>N.</given-names></name><name><surname>Vukelic</surname><given-names>K.</given-names></name><name><surname>JajacKnez</surname><given-names>A.</given-names></name><name><surname>Stimac</surname><given-names>D.</given-names></name></person-group> (<year>2015</year>). <article-title>Probiotics for standard triple <italic>Helicobacter pylori</italic> eradication: a randomized, double-blind, placebo-controlled trial.</article-title>
<source><italic>Medicine (Baltimore)</italic></source>
<volume>94</volume>:<issue>17</issue>. <pub-id pub-id-type="doi">10.1097/MD.0000000000000685</pub-id>
<?supplied-pmid 25929897?><pub-id pub-id-type="pmid">25929897</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hestvik</surname><given-names>E.</given-names></name><name><surname>Tylleskar</surname><given-names>T.</given-names></name><name><surname>Kaddu-Mulindwa</surname><given-names>D. H.</given-names></name><name><surname>Ndeezi</surname><given-names>G.</given-names></name><name><surname>Grahnquist</surname><given-names>L.</given-names></name><name><surname>Olafsdottir</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title><italic>Helicobacter pylori</italic> in apparently healthy children aged 0-12 years in urban Kampala. Uganda: a community-based cross sectional survey.</article-title>
<source><italic>BMC Gastroenterol.</italic></source>
<volume>10</volume>:<issue>62</issue>. <pub-id pub-id-type="doi">10.1186/1471-230X-10-62</pub-id>
<?supplied-pmid 20553588?><pub-id pub-id-type="pmid">20553588</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holcombe</surname><given-names>C.</given-names></name></person-group> (<year>1992</year>). <article-title><italic>Helicobacter pylori</italic>: the African enigma.</article-title>
<source><italic>Gut</italic></source>
<volume>33</volume>
<fpage>429</fpage>&#x02013;<lpage>431</lpage>. <pub-id pub-id-type="doi">10.1136/gut.33.4.429</pub-id><pub-id pub-id-type="pmid">1582581</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollander</surname><given-names>D.</given-names></name><name><surname>Tarnawski</surname><given-names>A.</given-names></name></person-group> (<year>1990</year>). <article-title>Is there a role for dietary essential fatty acids in gastroduodenal mucosal protection?</article-title>
<source><italic>J. Clin. Gastroenterol.</italic></source>
<volume>13(Suppl. 1)</volume>
<fpage>S72</fpage>&#x02013;<lpage>S74</lpage>. <?supplied-pmid 1940200?><pub-id pub-id-type="pmid">1940200</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000fc;tt</surname><given-names>P.</given-names></name><name><surname>Shchepetova</surname><given-names>J.</given-names></name><name><surname>L&#x000f5;ivukene</surname><given-names>K.</given-names></name><name><surname>Kullisaar</surname><given-names>T.</given-names></name><name><surname>Mikelsaar</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>Antagonistic activity of probiotic <italic>Lactobacilli</italic> and bifidobacteria against entero-and uropathogens.</article-title>
<source><italic>J. Appl. Microbiol.</italic></source>
<volume>1</volume>
<fpage>1324</fpage>&#x02013;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2672.2006.02857.x</pub-id>
<?supplied-pmid 16696680?><pub-id pub-id-type="pmid">16696680</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>L. M.</given-names></name><name><surname>Wu</surname><given-names>K. C.</given-names></name><name><surname>Mahida</surname><given-names>Y. R.</given-names></name><name><surname>Jenkins</surname><given-names>D.</given-names></name><name><surname>Hawkey</surname><given-names>C. J.</given-names></name></person-group> (<year>2000</year>). <article-title>Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa.</article-title>
<source><italic>Gut</italic></source>
<volume>47</volume>
<fpage>762</fpage>&#x02013;<lpage>770</lpage>. <pub-id pub-id-type="doi">10.1136/gut.47.6.762</pub-id>
<?supplied-pmid 11076873?><pub-id pub-id-type="pmid">11076873</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson-Henry</surname><given-names>K. C.</given-names></name><name><surname>Mitchell</surname><given-names>D. J.</given-names></name><name><surname>Avitzur</surname><given-names>Y.</given-names></name><name><surname>Galindo-Mata</surname><given-names>E.</given-names></name><name><surname>Jones</surname><given-names>N. L.</given-names></name><name><surname>Sherman</surname><given-names>P. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Probiotics reduce bacterial colonization and gastric inflammation in <italic>H</italic>. <italic>pylori-Infected</italic> mice.</article-title>
<source><italic>Dig. Dis. Sci.</italic></source>
<volume>49</volume>
<fpage>1095</fpage>&#x02013;<lpage>1102</lpage>. <pub-id pub-id-type="doi">10.1023/B:DDAS.0000037794.02040.c2</pub-id>
<?supplied-pmid 15387328?><pub-id pub-id-type="pmid">15387328</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamil</surname><given-names>R.</given-names></name><name><surname>Geier</surname><given-names>M. S.</given-names></name><name><surname>Butler</surname><given-names>R. N.</given-names></name><name><surname>Howarth</surname><given-names>G. S.</given-names></name></person-group> (<year>2007</year>). <article-title><italic>Lactobacillus rhamnosus</italic> GG exacerbates intestinal ulceration in a model of indomethacin-induced enteropathy.</article-title>
<source><italic>Dig. Dis. Sci.</italic></source>
<volume>1</volume>
<fpage>1247</fpage>&#x02013;<lpage>1252</lpage>. <pub-id pub-id-type="doi">10.1007/s10620-006-9443-3</pub-id>
<?supplied-pmid 17357841?><pub-id pub-id-type="pmid">17357841</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kate</surname><given-names>V.</given-names></name><name><surname>Ananthakrishnan</surname><given-names>N.</given-names></name><name><surname>Tovey</surname><given-names>F. I.</given-names></name></person-group> (<year>2013</year>). <article-title>Is <italic>Helicobacter pylori</italic> infection the primary cause of duodenal ulceration or a secondary factor? A review of the evidence.</article-title>
<source><italic>Gastroenterol. Res. Pract.</italic></source>
<volume>27</volume>:<issue>e425840</issue>.</mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>I.</given-names></name><name><surname>Nomura</surname><given-names>A. M. Y.</given-names></name><name><surname>Stemmermann</surname><given-names>G. N.</given-names></name><name><surname>Chyou</surname><given-names>P.-H.</given-names></name></person-group> (<year>1992</year>). <article-title>A prospective study of gastric and duodenal ulcer and its relation to smoking, alcohol, and diet.</article-title>
<source><italic>Am. J. Epidemiol.</italic></source>
<volume>1</volume>
<fpage>521</fpage>&#x02013;<lpage>530</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a116319</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katschinski</surname><given-names>B. D.</given-names></name><name><surname>Logan</surname><given-names>R. F.</given-names></name><name><surname>Edmond</surname><given-names>M.</given-names></name><name><surname>Langman</surname><given-names>M. J.</given-names></name></person-group> (<year>1990</year>). <article-title>Duodenal ulcer and refined carbohydrate intake: a case-control study assessing dietary fibre and refined sugar intake.</article-title>
<source><italic>Gut</italic></source>
<volume>1</volume>
<fpage>993</fpage>&#x02013;<lpage>996</lpage>. <pub-id pub-id-type="doi">10.1136/gut.31.9.993</pub-id>
<?supplied-pmid 2170250?><pub-id pub-id-type="pmid">2170250</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>M.</given-names></name><name><surname>Lastovica</surname><given-names>A. J.</given-names></name><name><surname>Atherton</surname><given-names>J. C.</given-names></name><name><surname>Louw</surname><given-names>J. A.</given-names></name></person-group> (<year>1999a</year>). <article-title>Heterogeneity in the <italic>Helicobacter pylori</italic> vacA and cagA genes: association with gastroduodenal disease in South Africa?</article-title>
<source><italic>Gut</italic></source>
<volume>45</volume>
<fpage>499</fpage>&#x02013;<lpage>502</lpage>. <?supplied-pmid 10486355?><pub-id pub-id-type="pmid">10486355</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kidd</surname><given-names>M.</given-names></name><name><surname>Louw</surname><given-names>J. A.</given-names></name><name><surname>Marks</surname><given-names>I. N.</given-names></name></person-group> (<year>1999b</year>). <article-title><italic>Helicobacter pylori</italic> in Africa: observations on an &#x02018;enigma within an enigma.</article-title>
<source><italic>J. Gastroenterol. Hepatol.</italic></source>
<volume>1</volume>
<fpage>851</fpage>&#x02013;<lpage>858</lpage>. <pub-id pub-id-type="doi">10.1046/j.1440-1746.1999.01975.x</pub-id>
<?supplied-pmid 10535465?><pub-id pub-id-type="pmid">10535465</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S. O.</given-names></name><name><surname>Sheikh</surname><given-names>H. I.</given-names></name><name><surname>Ha</surname><given-names>S.-D.</given-names></name><name><surname>Martins</surname><given-names>A.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name></person-group> (<year>2006</year>). <article-title>G-CSF-mediated inhibition of JNK is a key mechanism for <italic>Lactobacillus rhamnosus</italic>-induced suppression of TNF production in macrophages.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>8</volume>
<fpage>1958</fpage>&#x02013;<lpage>1971</lpage>. <pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00763.x</pub-id>
<?supplied-pmid 16889627?><pub-id pub-id-type="pmid">16889627</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodaman</surname><given-names>N.</given-names></name><name><surname>Pazos</surname><given-names>A.</given-names></name><name><surname>Schneider</surname><given-names>B. G.</given-names></name><name><surname>Piazuelo</surname><given-names>M. B.</given-names></name><name><surname>Mera</surname><given-names>R.</given-names></name><name><surname>Sobota</surname><given-names>R. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Human and <italic>Helicobacter pylori</italic> coevolution shapes the risk of gastric disease.</article-title>
<source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source>
<volume>111</volume>
<fpage>1455</fpage>&#x02013;<lpage>1460</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1318093111</pub-id>
<?supplied-pmid 24474772?><pub-id pub-id-type="pmid">24474772</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korhonen</surname><given-names>R.</given-names></name><name><surname>Kosonen</surname><given-names>O.</given-names></name><name><surname>Korpela</surname><given-names>R.</given-names></name><name><surname>Moilanen</surname><given-names>E.</given-names></name></person-group> (<year>2004</year>). <article-title>The expression of COX2 protein induced by <italic>Lactobacillus rhamnosus</italic> GG, endotoxin and lipoteichoic acid in T84 epithelial cells.</article-title>
<source><italic>Lett. Appl. Microbiol.</italic></source>
<volume>1</volume>
<fpage>19</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1111/j.1472-765X.2004.01531.x</pub-id>
<?supplied-pmid 15189283?><pub-id pub-id-type="pmid">15189283</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kort</surname><given-names>R.</given-names></name><name><surname>Sybesma</surname><given-names>W.</given-names></name></person-group> (<year>2012</year>). <article-title>Probiotics for every body.</article-title>
<source><italic>Trends Biotechnol.</italic></source>
<volume>30</volume>
<fpage>613</fpage>&#x02013;<lpage>615</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2012.09.002</pub-id>
<?supplied-pmid 23031355?><pub-id pub-id-type="pmid">23031355</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kort</surname><given-names>R.</given-names></name><name><surname>Westerik</surname><given-names>N.</given-names></name><name><surname>Serrano</surname><given-names>L. M.</given-names></name><name><surname>Douillard</surname><given-names>F.</given-names></name><name><surname>Gottstein</surname><given-names>W.</given-names></name><name><surname>Ananta</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>A novel consortium of <italic>Lactobacillus rhamnosus</italic> and <italic>Streptococcus thermophilus</italic> for increased access to functional fermented foods.</article-title>
<source><italic>Microb. Cell Fact.</italic></source>
<volume>14</volume>:<issue>195</issue>. <pub-id pub-id-type="doi">10.1186/s12934-015-0370-x</pub-id>
<?supplied-pmid 26643044?><pub-id pub-id-type="pmid">26643044</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lachlan</surname><given-names>G. W.</given-names></name><name><surname>Gilmour</surname><given-names>H. M.</given-names></name><name><surname>Jass</surname><given-names>J. J.</given-names></name></person-group> (<year>1988</year>). <article-title>Campylobacter pylori in central Africa.</article-title>
<source><italic>Br. Med. J. Clin. Res. Ed.</italic></source>
<volume>296</volume>:<issue>66</issue>
<pub-id pub-id-type="doi">10.1136/bmj.296.6614.66-b</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>E. K. Y.</given-names></name><name><surname>Tai</surname><given-names>E. K. K.</given-names></name><name><surname>Koo</surname><given-names>M. W. L.</given-names></name><name><surname>Wong</surname><given-names>H. P. S.</given-names></name><name><surname>Wu</surname><given-names>W. K. K.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2007a</year>). <article-title>Enhancement of gastric mucosal integrity by <italic>Lactobacillus rhamnosus</italic> GG.</article-title>
<source><italic>Life Sci.</italic></source>
<volume>16</volume>
<fpage>2128</fpage>&#x02013;<lpage>2136</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2007.03.018</pub-id>
<?supplied-pmid 17499310?><pub-id pub-id-type="pmid">17499310</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>E. K. Y.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Wong</surname><given-names>H. P. S.</given-names></name><name><surname>Wu</surname><given-names>W. K. K.</given-names></name><name><surname>Shin</surname><given-names>V. Y.</given-names></name><name><surname>Tai</surname><given-names>E. K. K.</given-names></name><etal/></person-group> (<year>2007b</year>). <article-title>Probiotic <italic>Lactobacillus rhamnosus</italic> GG enhances gastric ulcer healing in rats.</article-title>
<source><italic>Eur. J. Pharmacol.</italic></source>
<volume>22 565</volume>
<fpage>171</fpage>&#x02013;<lpage>179</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2007.02.050</pub-id>
<?supplied-pmid 17395175?><pub-id pub-id-type="pmid">17395175</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langat</surname><given-names>A. C.</given-names></name><name><surname>Ogutu</surname><given-names>E.</given-names></name><name><surname>Kamenwa</surname><given-names>R.</given-names></name><name><surname>Simiyu</surname><given-names>D. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Prevalence of <italic>Helicobacter pylori</italic> in children less than three years of age in health facilities in Nairobi Province.</article-title>
<source><italic>East Afr. Med. J.</italic></source>
<volume>83</volume>
<fpage>471</fpage>&#x02013;<lpage>477</lpage>. <?supplied-pmid 17447348?><pub-id pub-id-type="pmid">17447348</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Kim</surname><given-names>N.</given-names></name><name><surname>Nam</surname><given-names>R. H.</given-names></name><name><surname>Choi</surname><given-names>Y. J.</given-names></name><name><surname>Seo</surname><given-names>J. H.</given-names></name><name><surname>Lee</surname><given-names>H. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>No correlation of inflammation with colonization of <italic>Helicobacter pylori</italic> in the stomach of mice fed high-salt diet.</article-title>
<source><italic>J. Cancer Prev.</italic></source>
<volume>19</volume>
<fpage>144</fpage>&#x02013;<lpage>151</lpage>. <pub-id pub-id-type="doi">10.15430/JCP.2014.19.2.144</pub-id>
<?supplied-pmid 25337583?><pub-id pub-id-type="pmid">25337583</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>R.</given-names></name><name><surname>Fasano</surname><given-names>S.</given-names></name><name><surname>Madayiputhiya</surname><given-names>N.</given-names></name><name><surname>Morin</surname><given-names>N. P.</given-names></name><name><surname>Nataro</surname><given-names>J.</given-names></name><name><surname>Fasano</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Isolation, identification, and characterization of small bioactive peptides from <italic>Lactobacillus</italic> GG conditional media that exert both anti-gram-negative and gram-positive bactericidal activity.</article-title>
<source><italic>J. Pediatr. Gastroenterol. Nutr.</italic></source>
<volume>49</volume>:<issue>23</issue>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e3181924d1e</pub-id>
<?supplied-pmid 19465870?><pub-id pub-id-type="pmid">19465870</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mack</surname><given-names>D. R.</given-names></name><name><surname>Ahrn&#x000e9;</surname><given-names>S.</given-names></name><name><surname>Hyde</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Hollingsworth</surname><given-names>M. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Extracellular MUC3 mucin secretion follows adherence of <italic>Lactobacillus</italic> strains to intestinal epithelial cells in vitro.</article-title>
<source><italic>Gut</italic></source>
<volume>52</volume>
<fpage>827</fpage>&#x02013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1136/gut.52.6.827</pub-id>
<?supplied-pmid 12740338?><pub-id pub-id-type="pmid">12740338</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malfertheiner</surname><given-names>P.</given-names></name><name><surname>Megraud</surname><given-names>F.</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>C. A.</given-names></name><name><surname>Atherton</surname><given-names>J.</given-names></name><name><surname>Axon</surname><given-names>A. T. R.</given-names></name><name><surname>Bazzoli</surname><given-names>F.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Management of <italic>Helicobacter pylori</italic> infection&#x02014;the Maastricht IV/Florence consensus report.</article-title>
<source><italic>Gut</italic></source>
<volume>1</volume>
<fpage>646</fpage>&#x02013;<lpage>664</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2012-302084</pub-id>
<?supplied-pmid 22491499?><pub-id pub-id-type="pmid">22491499</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>S. L.</given-names></name></person-group> (<year>1978</year>). <article-title>A comparison of unrefined wheat and rice diets in the management of duodenal ulcer.</article-title>
<source><italic>Postgrad. Med. J.</italic></source>
<volume>1</volume>
<fpage>6</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1136/pgmj.54.627.6</pub-id>
<?supplied-pmid 625462?><pub-id pub-id-type="pmid">625462</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michetti</surname><given-names>P.</given-names></name></person-group> (<year>2001</year>). <article-title><italic>Lactobacilli</italic> for the management of <italic>Helicobacter pylori</italic>.</article-title>
<source><italic>Nutrition.</italic></source>
<volume>17</volume>
<fpage>268</fpage>&#x02013;<lpage>269</lpage>. <pub-id pub-id-type="doi">10.1016/S0899-9007(00)00475-5</pub-id>
<?supplied-pmid 11312076?><pub-id pub-id-type="pmid">11312076</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misciagna</surname><given-names>G.</given-names></name><name><surname>Cisternino</surname><given-names>A. M.</given-names></name><name><surname>Freudenheim</surname><given-names>J.</given-names></name></person-group> (<year>2000</year>). <article-title>Diet and duodenal ulcer.</article-title>
<source><italic>Dig Liver Dis.</italic></source>
<volume>32</volume>
<fpage>468</fpage>&#x02013;<lpage>472</lpage>. <pub-id pub-id-type="doi">10.1016/S1590-8658(00)80002-X</pub-id><pub-id pub-id-type="pmid">11057920</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Misiewicz</surname><given-names>G.</given-names></name><name><surname>Misiewicz</surname><given-names>J. J.</given-names></name><name><surname>Harris</surname><given-names>A.</given-names></name></person-group> (<year>1995</year>). <source><italic>Clinician&#x02019;s Manual on Helicobacter pylori</italic></source>. <publisher-loc>&#x00131;Wuhan</publisher-loc>: <publisher-name>Science Press</publisher-name>.</mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>H. M.</given-names></name><name><surname>Ally</surname><given-names>R.</given-names></name><name><surname>Wadee</surname><given-names>A.</given-names></name><name><surname>Wiseman</surname><given-names>M.</given-names></name><name><surname>Segal</surname><given-names>I.</given-names></name></person-group> (<year>2009</year>). <article-title>Major differences in the IgG subclass response to <italic>Helicobacter pylori</italic> in the first and third worlds.</article-title>
<source><italic>Scand. J. Gastroenterol.</italic></source>
<volume>37</volume>
<fpage>517</fpage>&#x02013;<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1080/00365520252903044</pub-id>
<?supplied-pmid 12059051?><pub-id pub-id-type="pmid">12059051</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>A.</given-names></name><name><surname>Solomon</surname><given-names>A.</given-names></name><name><surname>Beneck</surname><given-names>D.</given-names></name><name><surname>Cunningham-Rundles</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Positive association between <italic>Helicobacter pylori</italic> and gastroesophageal reflux disease in children.</article-title>
<source><italic>J. Pediatr. Gastroenterol. Nutr.</italic></source>
<volume>49</volume>:<issue>283</issue>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e31818eb8de</pub-id>
<?supplied-pmid 19525872?><pub-id pub-id-type="pmid">19525872</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myllyluoma</surname><given-names>E.</given-names></name><name><surname>Ahonen</surname><given-names>A.-M.</given-names></name><name><surname>Vapaatalo</surname><given-names>H.</given-names></name><name><surname>Kankuri</surname><given-names>E.</given-names></name></person-group> (<year>2008</year>). <article-title>Effects of multispecies probiotic combination on <italic>Helicobacter pylori</italic> infection in vitro.</article-title>
<source><italic>Clin. Vaccine Immunol.</italic></source>
<volume>15</volume>
<fpage>1472</fpage>&#x02013;<lpage>1482</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00080-08</pub-id>
<?supplied-pmid 18579692?><pub-id pub-id-type="pmid">18579692</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myllyluoma</surname><given-names>E.</given-names></name><name><surname>Kajander</surname><given-names>K.</given-names></name><name><surname>Mikkola</surname><given-names>H.</given-names></name><name><surname>Kyr&#x000f6;npalo</surname><given-names>S.</given-names></name><name><surname>Rasmussen</surname><given-names>M.</given-names></name><name><surname>Kankuri</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Probiotic intervention decreases serum gastrin-17 in <italic>Helicobacter pylori</italic> infection.</article-title>
<source><italic>Dig. Liver Dis.</italic></source>
<volume>39</volume>
<fpage>516</fpage>&#x02013;<lpage>523</lpage>. <pub-id pub-id-type="doi">10.1016/j.dld.2007.02.015</pub-id>
<?supplied-pmid 17433799?><pub-id pub-id-type="pmid">17433799</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myllyluoma</surname><given-names>E.</given-names></name><name><surname>Veijola</surname><given-names>L.</given-names></name><name><surname>Ahlroos</surname><given-names>T.</given-names></name><name><surname>Tynkkynen</surname><given-names>S.</given-names></name><name><surname>Kankuri</surname><given-names>E.</given-names></name><name><surname>Vapaatalo</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Probiotic supplementation improves tolerance to <italic>Helicobacter pylori</italic> eradication therapy &#x02013; a placebo-controlled, double-blind randomized pilot study.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>1</volume>
<fpage>1263</fpage>&#x02013;<lpage>1272</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2036.2005.02448.x</pub-id>
<?supplied-pmid 15882248?><pub-id pub-id-type="pmid">15882248</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naito</surname><given-names>Y.</given-names></name><name><surname>Yoshikawa</surname><given-names>T.</given-names></name><name><surname>Yoneta</surname><given-names>T.</given-names></name><name><surname>Yagi</surname><given-names>N.</given-names></name><name><surname>Matsuyama</surname><given-names>K.</given-names></name><name><surname>Arai</surname><given-names>M.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>A new gastric ulcer model in rats produced by ferrous iron and ascorbic acid injection.</article-title>
<source><italic>Digestion</italic></source>
<volume>56</volume>
<fpage>472</fpage>&#x02013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1159/000201278</pub-id>
<?supplied-pmid 8536816?><pub-id pub-id-type="pmid">8536816</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>R.</given-names></name><name><surname>Ziegler</surname><given-names>J. L.</given-names></name><name><surname>Casabonne</surname><given-names>D.</given-names></name><name><surname>Carpenter</surname><given-names>L.</given-names></name><name><surname>Gold</surname><given-names>B. D.</given-names></name><name><surname>Owens</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title><italic>Helicobacter pylori</italic> and cancer among adults in Uganda.</article-title>
<source><italic>Infect Agent Cancer</italic></source>
<volume>1</volume>:<issue>5</issue>. <pub-id pub-id-type="doi">10.1186/1750-9378-1-5</pub-id>
<?supplied-pmid 17150134?><pub-id pub-id-type="pmid">17150134</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nwokolo</surname><given-names>C. U.</given-names></name><name><surname>Freshwater</surname><given-names>D. A.</given-names></name><name><surname>O&#x02019;hare</surname><given-names>P.</given-names></name><name><surname>Randeva</surname><given-names>H. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Plasma ghrelin following cure of <italic>Helicobacter pylori</italic>.</article-title>
<source><italic>Gut.</italic></source>
<volume>52</volume>
<fpage>637</fpage>&#x02013;<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1136/gut.52.5.637</pub-id>
<?supplied-pmid 12692045?><pub-id pub-id-type="pmid">12692045</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouwehand</surname><given-names>A. C.</given-names></name><name><surname>Salminen</surname><given-names>S.</given-names></name><name><surname>Roberts</surname><given-names>P. J.</given-names></name><name><surname>Ovaska</surname><given-names>J.</given-names></name><name><surname>Salminen</surname><given-names>E.</given-names></name></person-group> (<year>2003</year>). <article-title>Disease-dependent adhesion of lactic acid bacteria to the human intestinal mucosa.</article-title>
<source><italic>Clin. Diagn. Lab. Immunol.</italic></source>
<volume>1</volume>
<fpage>643</fpage>&#x02013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1128/CDLI.10.4.643-646.2003</pub-id>
<?supplied-pmid 12853398?><pub-id pub-id-type="pmid">12853398</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>D. M.</given-names></name></person-group> (<year>2004</year>). <article-title>International variation.</article-title>
<source><italic>Oncogene</italic></source>
<volume>23</volume>
<fpage>6329</fpage>&#x02013;<lpage>6340</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1207726</pub-id>
<?supplied-pmid 15322508?><pub-id pub-id-type="pmid">15322508</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsonnet</surname><given-names>J.</given-names></name><name><surname>Replogle</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Hiatt</surname><given-names>R.</given-names></name></person-group> (<year>1997</year>). <article-title>Seroprevalence of CagA-Positive Strains among <italic>Helicobacter pylori</italic>&#x02014;Infected, healthy young adults.</article-title>
<source><italic>J. Infect Dis.</italic></source>
<volume>1</volume>
<fpage>1240</fpage>&#x02013;<lpage>1242</lpage>. <pub-id pub-id-type="doi">10.1086/593680</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pe&#x000f1;a</surname><given-names>J. A.</given-names></name><name><surname>Versalovic</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>). <article-title><italic>Lactobacillus rhamnosus</italic> GG decreases TNF-&#x003b1; production in lipopolysaccharide-activated murine macrophages by a contact-independent mechanism.</article-title>
<source><italic>Cell Microbiol.</italic></source>
<volume>1</volume>
<fpage>277</fpage>&#x02013;<lpage>285</lpage>. <?supplied-pmid 12675685?><pub-id pub-id-type="pmid">12675685</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>S.</given-names></name><name><surname>de Jong</surname><given-names>B. C.</given-names></name><name><surname>Solnick</surname><given-names>J. V.</given-names></name><name><surname>de la Luz Sanchez</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>P. L.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Infection with <italic>Helicobacter pylori</italic> Is associated with protection against tuberculosis.</article-title>
<source><italic>PLoS One</italic></source>
<volume>5</volume>:<issue>e8804</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0008804</pub-id>
<?supplied-pmid 20098711?><pub-id pub-id-type="pmid">20098711</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>M. I.</given-names></name><name><surname>Imholz</surname><given-names>N. C. E.</given-names></name><name><surname>Verhoeven</surname><given-names>T. L. A.</given-names></name><name><surname>Balzarini</surname><given-names>J.</given-names></name><name><surname>Van Damme</surname><given-names>E. J. M.</given-names></name><name><surname>Schols</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Lectin-Like molecules of <italic>Lactobacillus rhamnosus</italic> GG inhibit pathogenic <italic>Escherichia coli</italic> and <italic>Salmonella</italic> biofilm formation.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0161337</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0161337</pub-id>
<?supplied-pmid 27537843?><pub-id pub-id-type="pmid">27537843</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ricci</surname><given-names>C.</given-names></name><name><surname>Holton</surname><given-names>J.</given-names></name><name><surname>Vaira</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Diagnosis of <italic>Helicobacter pylori</italic>: invasive and non-invasive tests.</article-title>
<source><italic>Best Pract. Res. Clin. Gastroenterol.</italic></source>
<volume>21</volume>
<fpage>299</fpage>&#x02013;<lpage>313</lpage>.<pub-id pub-id-type="pmid">17382278</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinkinen</surname><given-names>M.</given-names></name><name><surname>Jalava</surname><given-names>K.</given-names></name><name><surname>Westermarck</surname><given-names>E.</given-names></name><name><surname>Salminen</surname><given-names>S.</given-names></name><name><surname>Ouwehand</surname><given-names>A. C.</given-names></name></person-group> (<year>2003</year>). <article-title>Interaction between probiotic lactic acid bacteria and canine enteric pathogens: a risk factor for intestinal <italic>Enterococcus faecium</italic> colonization?</article-title>
<source><italic>Vet. Microbiol.</italic></source> 20 <volume>92</volume>
<fpage>111</fpage>&#x02013;<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-1135(02)00356-5</pub-id>
<?supplied-pmid 12488075?><pub-id pub-id-type="pmid">12488075</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>S. E.</given-names></name><name><surname>Morrison-Rees</surname><given-names>S.</given-names></name><name><surname>Samuel</surname><given-names>D. G.</given-names></name><name><surname>Thorne</surname><given-names>K.</given-names></name><name><surname>Akbari</surname><given-names>A.</given-names></name><name><surname>Williams</surname><given-names>J. G.</given-names></name></person-group> (<year>2016</year>). <article-title>Review article: the prevalence of <italic>Helicobacter pylori</italic> and the incidence of gastric cancer across Europe.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>1</volume>
<fpage>334</fpage>&#x02013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1111/apt.13474</pub-id>
<?supplied-pmid 26592801?><pub-id pub-id-type="pmid">26592801</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rokka</surname><given-names>S.</given-names></name><name><surname>Myllykangas</surname><given-names>S.</given-names></name><name><surname>Joutsjoki</surname><given-names>V.</given-names></name></person-group> (<year>2008</year>). <article-title>Effect of specific colostral antibodies and selected <italic>Lactobacilli</italic> on the adhesion of <italic>Helicobacter pylori</italic> on AGS cells and the <italic>Helicobacter</italic>-induced IL-8 production.</article-title>
<source><italic>Scand. J. Immunol.</italic></source>
<volume>1</volume>
<fpage>280</fpage>&#x02013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3083.2008.02138.x</pub-id>
<?supplied-pmid 18627549?><pub-id pub-id-type="pmid">18627549</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouvroy</surname><given-names>D.</given-names></name><name><surname>Bogaerts</surname><given-names>J.</given-names></name><name><surname>Nsengiumwa</surname><given-names>O.</given-names></name><name><surname>Omar</surname><given-names>M.</given-names></name><name><surname>Versailles</surname><given-names>L.</given-names></name><name><surname>Haot</surname><given-names>J.</given-names></name></person-group> (<year>1987</year>). <article-title>gastritis, and peptic ulcer disease in central Africa.</article-title>
<source><italic>BMJ</italic></source>
<volume>295</volume>
<fpage>1174</fpage>&#x02013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.295.6607.1174</pub-id><pub-id pub-id-type="pmid">3120933</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rydning</surname><given-names>A.</given-names></name><name><surname>Aadland</surname><given-names>E.</given-names></name><name><surname>Berstad</surname><given-names>A.</given-names></name><name><surname>Odegaard</surname><given-names>B.</given-names></name></person-group> (<year>1982</year>). <article-title>Prophylactic effect of dietary fibre in duodenal ulcer disease.</article-title>
<source><italic>Lancet</italic></source>
<volume>320</volume>
<fpage>736</fpage>&#x02013;<lpage>739</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(82)90922-9</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>I.</given-names></name><name><surname>Ally</surname><given-names>R.</given-names></name><name><surname>Mitchell</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title><italic>Helicobacter pylori</italic>&#x02014;an African perspective.</article-title>
<source><italic>QJM</italic></source>
<volume>1</volume>
<fpage>561</fpage>&#x02013;<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1093/qjmed/94.10.561</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segamwenge</surname><given-names>I. L.</given-names></name><name><surname>Kagimu</surname><given-names>M.</given-names></name><name><surname>Ocama</surname><given-names>P.</given-names></name><name><surname>Opio</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>The Utility of the <italic>Helicobacter pylori</italic> stool antigen test in managing dyspepsia: an experience from a low resource setting.</article-title>
<source><italic>Afr. Health Sci.</italic></source>
<volume>1</volume>
<fpage>829</fpage>&#x02013;<lpage>834</lpage>. <pub-id pub-id-type="doi">10.4314/ahs.v14i4.9</pub-id>
<?supplied-pmid 25834490?><pub-id pub-id-type="pmid">25834490</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segers</surname><given-names>M. E.</given-names></name><name><surname>Lebeer</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Towards a better understanding of <italic>Lactobacillus rhamnosus</italic> GG - host interactions.</article-title>
<source><italic>Microb. Cell Fact.</italic></source> 29 13:S7. <pub-id pub-id-type="doi">10.1186/1475-2859-13-S1-S7</pub-id>
<?supplied-pmid 25186587?><pub-id pub-id-type="pmid">25186587</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sybesma</surname><given-names>W.</given-names></name><name><surname>Kort</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>Y.-K.</given-names></name></person-group> (<year>2015</year>). <article-title>Locally sourced probiotics, the next opportunity for developing countries?</article-title>
<source><italic>Trends Biotechnol.</italic></source>
<volume>33</volume>
<fpage>197</fpage>&#x02013;<lpage>200</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibtech.2015.01.002</pub-id>
<?supplied-pmid 25812840?><pub-id pub-id-type="pmid">25812840</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sybesma</surname><given-names>W.</given-names></name><name><surname>Molenaar</surname><given-names>D.</given-names></name><name><surname>IJcken</surname><given-names>W.</given-names></name><name><surname>van Venema</surname><given-names>K.</given-names></name><name><surname>Kort</surname><given-names>R.</given-names></name></person-group> (<year>2013</year>). <article-title>Genome instability in <italic>Lactobacillus rhamnosus</italic> GG.</article-title>
<source><italic>Appl. Environ. Microbiol.</italic></source>
<volume>1</volume>
<fpage>2233</fpage>&#x02013;<lpage>2239</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.03566-12</pub-id>
<?supplied-pmid 23354703?><pub-id pub-id-type="pmid">23354703</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H.</given-names></name><name><surname>Albrecht</surname><given-names>P.</given-names></name><name><surname>Topczewska-Cabanek</surname><given-names>A.</given-names></name></person-group> (<year>2009</year>). <article-title>Randomized, double-blind, placebo-controlled trial: effect of <italic>Lactobacillus</italic> GG supplementation on <italic>Helicobacter pylori</italic> eradication rates and side effects during treatment in children.</article-title>
<source><italic>J. Pediatr. Gastroenterol. Nutr.</italic></source>
<volume>48</volume>
<fpage>431</fpage>&#x02013;<lpage>436</lpage>. <pub-id pub-id-type="doi">10.1097/MPG.0b013e318182e716</pub-id><pub-id pub-id-type="pmid">19330931</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H.</given-names></name><name><surname>Sk&#x000f3;rka</surname><given-names>A.</given-names></name><name><surname>Ruszczy&#x00144;ski</surname><given-names>M.</given-names></name><name><surname>Gieruszczak-Bia&#x00142;ek</surname><given-names>D.</given-names></name></person-group> (<year>2007</year>). <article-title>Meta-analysis: <italic>Lactobacillus</italic> GG for treating acute diarrhoea in children.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>1</volume>
<fpage>871</fpage>&#x02013;<lpage>881</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03282.x</pub-id>
<?supplied-pmid 17402990?><pub-id pub-id-type="pmid">17402990</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>K.</given-names></name><name><surname>Sakurai</surname><given-names>T.</given-names></name><name><surname>Kogo</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>). <article-title>Relationship between prostaglandin E 2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells.</article-title>
<source><italic>Vascul. Pharmacol.</italic></source>
<volume>44</volume>
<fpage>411</fpage>&#x02013;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.vph.2006.02.009</pub-id>
<?supplied-pmid 16651031?><pub-id pub-id-type="pmid">16651031</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>L.</given-names></name><name><surname>Cockayne</surname><given-names>A.</given-names></name><name><surname>Spiller</surname><given-names>R. C.</given-names></name></person-group> (<year>1994</year>). <article-title>Inhibitory effect of polyunsaturated fatty acids on the growth of <italic>Helicobacter pylori</italic>: a possible explanation of the effect of diet on peptic ulceration.</article-title>
<source><italic>Gut</italic></source>
<volume>1</volume>
<fpage>1557</fpage>&#x02013;<lpage>1561</lpage>. <pub-id pub-id-type="doi">10.1136/gut.35.11.1557</pub-id>
<?supplied-pmid 7828972?><pub-id pub-id-type="pmid">7828972</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovey</surname><given-names>F. I.</given-names></name></person-group> (<year>2009</year>). <article-title>Staple diets and duodenal ulcer prevalence.</article-title>
<source><italic>Int. Health</italic></source>
<volume>1</volume>
<fpage>124</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1016/j.inhe.2009.09.004</pub-id>
<?supplied-pmid 24036556?><pub-id pub-id-type="pmid">24036556</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovey</surname><given-names>F. I.</given-names></name><name><surname>Tunstall</surname><given-names>M.</given-names></name></person-group> (<year>1975</year>). <article-title>Duodenal ulcer in black populations in Africa south of the Sahara.</article-title>
<source><italic>Gut</italic></source>
<volume>1</volume>
<fpage>564</fpage>&#x02013;<lpage>576</lpage>. <pub-id pub-id-type="doi">10.1136/gut.16.7.564</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsongo</surname><given-names>L.</given-names></name><name><surname>Nakavuma</surname><given-names>J.</given-names></name><name><surname>Mugasa</surname><given-names>C.</given-names></name><name><surname>Kamalha</surname><given-names>E.</given-names></name></person-group> (<year>2015</year>). <article-title><italic>Helicobacter pylori</italic> among patients with symptoms of gastroduodenal ulcer disease in rural Uganda.</article-title>
<source><italic>Infect Ecol. Epidemiol.</italic></source>
<volume>5</volume>:<issue>26785</issue>. <pub-id pub-id-type="doi">10.3402/iee.v5.26785</pub-id>
<?supplied-pmid 26560860?><pub-id pub-id-type="pmid">26560860</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaezi</surname><given-names>M. F.</given-names></name><name><surname>Falk</surname><given-names>G. W.</given-names></name><name><surname>Peek</surname><given-names>R. M.</given-names></name><name><surname>Vicari</surname><given-names>J. J.</given-names></name><name><surname>Goldblum</surname><given-names>J. R.</given-names></name><name><surname>Perez-Perez</surname><given-names>G. I.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>CagA-positive strains of <italic>Helicobacter pylori</italic> may protect against Barrett&#x02019;s esophagus.</article-title>
<source><italic>Am. J. Gastroenterol.</italic></source>
<volume>95</volume>
<fpage>2206</fpage>&#x02013;<lpage>2211</lpage>. <pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.02305.x</pub-id>
<?supplied-pmid 11007219?><pub-id pub-id-type="pmid">11007219</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vicari</surname><given-names>J. J.</given-names></name><name><surname>Peek</surname><given-names>R. M.</given-names></name><name><surname>Falk</surname><given-names>G. W.</given-names></name><name><surname>Goldblum</surname><given-names>J. R.</given-names></name><name><surname>Easley</surname><given-names>K. A.</given-names></name><name><surname>Schnell</surname><given-names>J.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>The seroprevalence of cagA-positive <italic>Helicobacter pylori</italic> strains in the spectrum of gastroesophageal reflux disease.</article-title>
<source><italic>Gastroenterology</italic></source>
<volume>115</volume>
<fpage>50</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/S0016-5085(98)70364-6</pub-id>
<?supplied-pmid 9649458?><pub-id pub-id-type="pmid">9649458</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wabinga</surname><given-names>H.</given-names></name></person-group> (<year>1996</year>). <article-title>Frequency of <italic>Helicobacter pylori</italic> in gastroscopic biopsy of Ugandan Africans.</article-title>
<source><italic>East Afr. Med J.</italic></source>
<volume>73</volume>
<fpage>691</fpage>&#x02013;<lpage>693</lpage>. <?supplied-pmid 8997853?><pub-id pub-id-type="pmid">8997853</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.-Q.</given-names></name><name><surname>Terry</surname><given-names>P. D.</given-names></name><name><surname>Yan</surname><given-names>H.</given-names></name></person-group> (<year>2009</year>). <article-title>Review of salt consumption and stomach cancer risk: epidemiological and biological evidence.</article-title>
<source><italic>World J. Gastroenterol.</italic></source>
<volume>14</volume>
<fpage>2204</fpage>&#x02013;<lpage>2213</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.15.2204</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerik</surname><given-names>N.</given-names></name><name><surname>Kort</surname><given-names>R.</given-names></name><name><surname>Sybesma</surname><given-names>W.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name></person-group> (<year>2018</year>). <article-title><italic>Lactobacillus rhamnosus</italic> probiotic food as a tool for empowerment across the value Chain in Africa.</article-title>
<source><italic>Front Microbiol.</italic></source>
<volume>9</volume>:<issue>1501</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2018.01501</pub-id>
<?supplied-pmid 30042747?><pub-id pub-id-type="pmid">30042747</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerik</surname><given-names>N.</given-names></name><name><surname>Wacoo</surname><given-names>A. P.</given-names></name><name><surname>Sybesma</surname><given-names>W.</given-names></name><name><surname>Kort</surname><given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>Novel production protocol for small-scale manufacture of probiotic fermented foods.</article-title>
<source><italic>J. Vis. Exp.</italic></source>
<volume>115</volume>:<issue>e54365</issue>. <pub-id pub-id-type="doi">10.3791/54365</pub-id>
<?supplied-pmid 27684196?><pub-id pub-id-type="pmid">27684196</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Jing</surname><given-names>J.-J.</given-names></name><name><surname>Gong</surname><given-names>Y.-H.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>W.-L.</given-names></name><name><surname>Piao</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Changes in biological and virulent characteristics of <italic>Helicobacter pylori</italic> exposed to high salt.</article-title>
<source><italic>Asian Pac. J. Cancer Prev.</italic></source>
<volume>12</volume>
<fpage>2637</fpage>&#x02013;<lpage>2641</lpage>. <?supplied-pmid 22320966?><pub-id pub-id-type="pmid">22320966</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>F.</given-names></name><name><surname>Polk</surname><given-names>D. B.</given-names></name></person-group> (<year>2002</year>). <article-title>Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells.</article-title>
<source><italic>J. Biol. Chem.</italic></source>
<volume>27</volume>
<fpage>50959</fpage>&#x02013;<lpage>50965</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M207050200</pub-id>
<?supplied-pmid 12393915?><pub-id pub-id-type="pmid">12393915</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>W.</given-names></name><name><surname>Held</surname><given-names>M.</given-names></name><name><surname>Lagergren</surname><given-names>J.</given-names></name><name><surname>Engstrand</surname><given-names>L.</given-names></name><name><surname>Blot</surname><given-names>W. J.</given-names></name><name><surname>McLaughlin</surname><given-names>J. K.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title><italic>Helicobacter pylori</italic> infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia.</article-title>
<source><italic>J. Natl. Cancer Inst.</italic></source>
<volume>96</volume>
<fpage>388</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djh057</pub-id>
<?supplied-pmid 14996860?><pub-id pub-id-type="pmid">14996860</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zamani</surname><given-names>M.</given-names></name><name><surname>Ebrahimtabar</surname><given-names>F.</given-names></name><name><surname>Zamani</surname><given-names>V.</given-names></name><name><surname>Miller</surname><given-names>W. H.</given-names></name><name><surname>Alizadeh-Navaei</surname><given-names>R.</given-names></name><name><surname>Shokri-Shirvani</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Systematic review with meta-analysis: the worldwide prevalence of <italic>Helicobacter pylori</italic> infection.</article-title>
<source><italic>Aliment Pharmacol. Ther.</italic></source>
<volume>47</volume>
<fpage>868</fpage>&#x02013;<lpage>876</lpage>. <pub-id pub-id-type="doi">10.1111/apt.14561</pub-id>
<?supplied-pmid 29430669?><pub-id pub-id-type="pmid">29430669</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Caicedo</surname><given-names>R.</given-names></name><name><surname>Neu</surname><given-names>J.</given-names></name></person-group> (<year>2005</year>). <article-title>Alive and dead <italic>Lactobacillus rhamnosus</italic> GG decrease tumor necrosis factor-&#x003b1;&#x02013;induced interleukin-8 production in caco-2 cells.</article-title>
<source><italic>J. Nutr.</italic></source>
<volume>1</volume>
<fpage>1752</fpage>&#x02013;<lpage>1756</lpage>. <pub-id pub-id-type="doi">10.1093/jn/135.7.1752</pub-id>
<?supplied-pmid 15987860?><pub-id pub-id-type="pmid">15987860</pub-id></mixed-citation></ref></ref-list></back></article>